<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Neuropathol Commun</journal-id><journal-id journal-id-type="iso-abbrev">Acta Neuropathol Commun</journal-id><journal-title-group><journal-title>Acta Neuropathologica Communications</journal-title></journal-title-group><issn pub-type="epub">2051-5960</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4994259</article-id><article-id pub-id-type="publisher-id">364</article-id><article-id pub-id-type="doi">10.1186/s40478-016-0364-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Telomere shortening leads to an acceleration of synucleinopathy and impaired microglia response in a genetic mouse model</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Scheffold</surname><given-names>Annika</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Holtman</surname><given-names>Inge R.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dieni</surname><given-names>Sandra</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Brouwer</surname><given-names>Nieske</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Katz</surname><given-names>Sarah-Fee</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Jebaraj</surname><given-names>Billy Michael Chelliah</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kahle</surname><given-names>Philipp J.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Hengerer</surname><given-names>Bastian</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Lechel</surname><given-names>Andr&#x000e9;</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Stilgenbauer</surname><given-names>Stephan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Boddeke</surname><given-names>Erik W. G. M.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Eggen</surname><given-names>Bart J. L.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rudolph</surname><given-names>Karl-Lenhard</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Biber</surname><given-names>Knut</given-names></name><address><email>knut.biber@uniklinik-freiburg.de</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label>Department of Internal Medicine III, University of Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany </aff><aff id="Aff2"><label>2</label>Department of Neuroscience, Section Medical Physiology, University of Groningen, University Medical Center Groningen, 9713 AV Groningen, The Netherlands </aff><aff id="Aff3"><label>3</label>Department for Psychiatry and Psychotherapy, Molecular Psychiatry, Freiburg University Hospital, Hauptstrasse 5, 79104 Freiburg, Germany </aff><aff id="Aff4"><label>4</label>Department of Internal Medicine I, University of Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany </aff><aff id="Aff5"><label>5</label>Center of Neurology and Hertie-Institute for Clinical Brain Research, University of T&#x000fc;bingen, T&#x000fc;bingen, Germany </aff><aff id="Aff6"><label>6</label>Boehringer Ingelheim Pharma GmbH &#x00026; Co. KG, Biberach an der Riss, Germany </aff><aff id="Aff7"><label>7</label>Leibniz Institute for Age Research, Beutenbergstr. 11, 07745 Jena, Germany </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>8</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>8</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>4</volume><issue>1</issue><elocation-id>87</elocation-id><history><date date-type="received"><day>10</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>11</day><month>8</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><p>Parkinson&#x02019;s disease is one of the most common neurodegenerative disorders of the elderly and ageing hence described to be a major risk factor. Telomere shortening as a result of the inability to fully replicate the ends of linear chromosomes is one of the hallmarks of ageing. The role of telomere dysfunction in neurological diseases and the ageing brain is not clarified and there is an ongoing discussion whether telomere shortening is linked to Parkinson&#x02019;s disease. Here we studied a mouse model of Parkinson&#x02019;s disease (Thy-1 [A30P] <italic>&#x003b1;-</italic>synuclein transgenic mouse model) in the background of telomere shortening (Terc knockout mouse model). <italic>&#x003b1;-s</italic>ynuclein transgenic mice with short telomeres (&#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup>) developed an accelerated disease with significantly decreased survival. This accelerated phenotype of mice with short telomeres was characterized by a declined motor performance and an increased formation of &#x003b1;-synuclein aggregates. Immunohistochemical analysis and mRNA expression studies revealed that the disease end-stage brain stem microglia showed an impaired response in &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> microglia animals. These results provide the first experimental data that telomere shortening accelerates <italic>&#x003b1;-</italic>synuclein pathology that is linked to limited microglia function in the brainstem.</p><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s40478-016-0364-x) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Parkinson&#x02019;s disease</kwd><kwd>&#x003b1;<italic>-</italic>synuclein</kwd><kwd>Telomeres</kwd><kwd>Microglia</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>BI 668/2-2 and BI 668/5-1</award-id><principal-award-recipient><name><surname>Biber</surname><given-names>Knut</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>Parkinson&#x02019;s disease (PD) is a neurodegenerative disease in the elderly with an average age of onset of 60&#x000a0;years, with 8-18/100,000 newly diagnosed patients every year [<xref ref-type="bibr" rid="CR1">1</xref>]. The main characteristic of PD is the death of dopaminergic neurons in the substantia nigra pars compacta (SN) in the brain of PD patients. Several missense mutations and genomic multiplications of the &#x003b1;-synuclein gene (<italic>SCNA</italic>) are described to cause the autosomal dominant hereditary PD and SCNA polymorphisms are major genetic risk factors for PD [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p>Aggregated &#x003b1;-synuclein protein forms immuno-reactive inclusions which incorporate in typical Lewy bodies and Lewy neurites [<xref ref-type="bibr" rid="CR3">3</xref>] and induce neuroinflammation in humans [<xref ref-type="bibr" rid="CR4">4</xref>]. As a pathological hallmark of PD, Lewy bodies were for a long time thought to be the key component of the neuronal cell death and a pathological hallmark of PD, however the process of soluble monomers into insoluble &#x003b1;-synuclein aggregates reached increasing attention as the disease causative step [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. Prefibrilliar forms induce cell death in vitro [<xref ref-type="bibr" rid="CR8">8</xref>] but the causal mechanism of &#x003b1;-synuclein oligomerization has not yet been identified.</p><p>Microglia are of crucial importance in brain pathology, and these cells are currently in focus as potential targets for improved therapies [<xref ref-type="bibr" rid="CR9">9</xref>]. It has now been established in mice that microglia arise from the yolk sac erythromyeloid precursors that invade the brain rudiment around embryonic day 9.5 in the mouse [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. Based on cell morphology it was originally assumed that the ramified (branched) microglia in the healthy brain are inactive or resting and that microglia under pathological conditions acquire an amoeboid morphology described as &#x0201c;activated microglia&#x0201d;. Since ramified microglia are by no means resting cells [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>] the simple concept of microglia &#x0201c;activation&#x0201d; in disease is misleading. Instead of becoming &#x0201c;activated&#x0201d; microglia undergo a disease-specific phenotype shift, which might be associated with tissue repair or with enhanced pro-inflammatory activity, thus contributing to the disease [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. Thus, understanding how microglia function in diseases is regulated and addressing the contribution of microglia to brain diseases is of pivotal importance.</p><p>Parkinson&#x02019;s disease is highly connected to neuroinflammatory changes with the presence of amoeboid or reactive microglia both in patients and various Parkinson&#x02019;s disease models [<xref ref-type="bibr" rid="CR24">24</xref>]. However, the precise role of microglia in the disease is still under debate as potential detrimental as well as protective properties of these cells have been published [<xref ref-type="bibr" rid="CR25">25</xref>]. For example microglia may also restrict the disease by gluthatione peroxidase expression which is protective against Lewy body formation [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p>Since Parkinson&#x02019;s disease is a prominent disease of the elderly, ageing is supposed to be a major risk factor [<xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>]. Microglia are affected in the ageing brain and nevertheless it is still not explained, if ageing related changes or chronic disease prime glial cells to induce neurotoxicity or whether microglia ageing impairs their function which in turn may promote neurodegeneration [<xref ref-type="bibr" rid="CR30">30</xref>]. Several pathways and key genes, as well as telomere shortening which occurs with cell replication are involved in the process of ageing [<xref ref-type="bibr" rid="CR31">31</xref>]. Telomere length is therefore considered to be an indicator of biological ageing. Intensive studies have confirmed, that chronic diseases lead to accelerated shortening of the chromosomal ends [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Telomere shortening in microglia cells of ageing rats has already been described in vitro as well as in vivo [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Telomere shortening of microglia leads to cellular senescence and is associated with amyloid dementia [<xref ref-type="bibr" rid="CR36">36</xref>].</p><p>A possible link between telomere shortening in peripheral leukocytes and Parkinson&#x02019;s disease has been addressed with inconclusive results. In some studies telomere shortage was linked to accelerated disease, whereas in other reports there was no clear correlation between telomere length and disease progression [<xref ref-type="bibr" rid="CR37">37</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>].</p><p>In order to further understand the potential role of telomere shortening in Parkinson&#x02019;s disease pathology we crossed the &#x003b1;-synuclein transgenic Parkinson mouse model Thy-1 [A30P] with the Terc knockout mice, a telomere erosion-based ageing mouse model.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>Mouse models</title><p>The &#x003b1;SYN transgenic mice used here express the human mutant [A30P] &#x003b1;<italic>-</italic>synuclein under control of the neuron-specific Thy-1 promoter [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. Genotyping of mice was performed as previously described [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>].</p><p>Terc knockout mice carry a homozygous deletion of the telomerase RNA subunit Terc. Thereby telomerase activity is lost [<xref ref-type="bibr" rid="CR44">44</xref>]. Like the &#x003b1;SYN transgenic mice, Terc knockout mice are in the same C57/BL6/J strain, minimizing genetic background influences.</p><p>For generating homozygous &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice, heterozygous &#x003b1;SYN<sup>tg/wt</sup> Terc<sup>+/-</sup> mice were crossed to get the first generation of Terc knockout (&#x003b1;SYN<sup>tg/tg</sup> Terc<sup>-/-</sup> G1). Crossing of the homozygous 1st Terc<sup>-/-</sup> generation was performed to obtain the 2nd generation, and crossing of the 2nd generation results in the 3rd generation of Terc knockout mice.</p><p>All mice were maintained and bred at the animal facility of Ulm University (Tierforschungszentrum Ulm). The mice were maintained in a pathogen-free environment (SPF IVC barrier) with a 14/10&#x000a0;h&#x000a0;day and night rhythm. Food and drinking water were available <italic>ad libitum</italic>. Temperature and humidity were controlled at 23&#x000a0;&#x000b0;C.</p><p>All animal experiments were performed according to protocols approved by the state government of Baden W&#x000fc;rttemberg, following the animal welfare guidelines.</p></sec><sec id="Sec4"><title>Beamwalk</title><p>Beam walking is a well established test to monitor motor coordination and balance of rodents. Mice were trained for three consecutive days to cross a squared, wooden beam to reach an enclosed platform. The latency and the footslips to traverse the beam were measured. Mice were trained for four consecutive days on the squared 28&#x000a0;mm beam. Each mouse completed three trainings per day. For final testing, three rounds on four different beams were performed. The squared beams had a side length of 5, 12, and 28&#x000a0;mm, the round beams had a diameter of 11, 17, and 28&#x000a0;mm. Parameters such as the latency and footslips and the number of falls were recorded and analyzed as previously described [<xref ref-type="bibr" rid="CR45">45</xref>].</p></sec><sec id="Sec5"><title>Exploratory behavior</title><p>Exploratory behavior of the transgenic mice was analyzed using the Viewer<sup>3</sup> system (Biobserve) [<xref ref-type="bibr" rid="CR46">46</xref>]. This system contains an activity box, which is subdivided into three different zones, the border, the intermediate and the center zone. During the experiment, several parameters such as the activity, duration in different zones and the totally walked distance were recorded. Mice were put into the exploratory fields for 10&#x000a0;min. After each run, boxes were cleaned with ddH<sub>2</sub>O and 70&#x000a0;% Ethanol to remove pheromones.</p></sec><sec id="Sec6"><title>Transcardial perfusion and brain tissue collection</title><p>&#x003b1;SYN transgenic symptomatic mice develop a phenotype with severe motoric imbalances and dysfunctions of brainstem and cerebellum [<xref ref-type="bibr" rid="CR42">42</xref>]. Dead criteria were defined when the mice start to develop motoric imbalances and their walk was disturbed. To collect brain tissue, mice were transcardially perfused. Briefly, mice were anaesthetized with Ketamin/Xylazin. After loss of reflexes, the heart cavity of the mouse was opened, the mouse has been perfused for 3&#x000a0;min using ice-cold PBS to flush and remove blood from the vessels. The brain was dissected and cut into the hemispheres, one hemisphere was snap-frozen in liquid nitrogen and stored at &#x02212;80&#x000a0;&#x000b0;C, the other half was fixed in 4&#x000a0;% PFA overnight and embedded in paraffin the next day.</p></sec><sec id="Sec7"><title>&#x003b1;-Synuclein staining on proteinase K digested paraffin embedded tissue blots (PK-PET Blot)</title><p>The Proteinase K digested paraffin-embedded tissue (PK-PET) blot was performed as described previously [<xref ref-type="bibr" rid="CR47">47</xref>], with minor modifications in the protocol. A 0.45&#x000a0;&#x003bc;m PVDF membrane (Serva Electrophoresis) was cut into sections, activated in methanol and transferred into water. Five micrometer thick paraffin sections were cut using the microtome and collected onto the membrane. The sections were then dried for 30&#x000a0;min at 55&#x000a0;&#x000b0;C. Deparaffinization was done in 100&#x000a0;% Xylol for 10&#x000a0;min followed by rehydration through an ethanol series (100&#x000a0;%, 95&#x000a0;%, 70&#x000a0;%) for 5&#x000a0;min each. Membranes were washed with TBS for 5&#x000a0;min and digested using 10&#x000a0;&#x003bc;g/ml Proteinase K at 55&#x000a0;&#x000b0;C in PK digest buffer (10&#x000a0;mM Tris HCl pH7.8, 100&#x000a0;mM NaCl, 0.1&#x000a0;% Brij) for 15&#x000a0;h. Membranes were washed for three times in TBS-T for 5&#x000a0;min and then incubated in 3&#x000a0;% H<sub>2</sub>O<sub>2</sub> for 5&#x000a0;min to block endogenous peroxidases. After a further wash step denaturation with 4&#x000a0;M guanidine isothiocyanate in 10&#x000a0;mM Tris-HCl pH&#x000a0;7,8 was done for 15&#x000a0;min to retrieve epitopes.</p><p>Membranes were blocked in 0.2&#x000a0;% casein dissolved in TBS-T (i-Block) for 60&#x000a0;min at room temperature and then incubated with primary anti-&#x003b1;-synuclein antibody (1:1000 dilution, BD Cat.no. 610787) overnight at 4&#x000a0;&#x000b0;C in a wet chamber. After 3 washes with TBS-T, membranes were incubated with biotinylated secondary antibody (1:500 in i-Block) for 1&#x000a0;h at room temperature. Detection was done after several washes using the Avidin/Biotin Technology (Vectastain Elite ABC Kit, Vector Laboratories). Reaction was stopped by washing the membranes in distilled water.</p></sec><sec id="Sec8"><title>Determination of telomere length by quantitative fluorescence <italic>in situ</italic> hybridization</title><p>Telomere lenght was analyzed in the brainstem, where most of the studies were performed, using a previously described protocol [<xref ref-type="bibr" rid="CR48">48</xref>]. In short, tissues were digested in prewarmed pepsin solution (100&#x000a0;mg of pepsin, 100&#x000a0;ml of H<sub>2</sub>O, 84&#x000a0;ml of conc. HCl) for 15&#x000a0;min at 37&#x000a0;&#x000b0;C and washed for three times with PBS. After dehydration series, slides were dried and hybridization mix was added (1&#x000a0;mM Tris pH&#x000a0;7.2, 25&#x000a0;mM magnesiumchloride, 9&#x000a0;mM citricacid, 82&#x000a0;mM disodiumhydrogenphosphate, 70&#x000a0;%&#x000a0;&#x003bc;l formamide deionized, 25&#x000a0;&#x003bc;g/ml peptide nucleic acid (PNA) probe (Panagene), 5&#x000a0;% blocking reagent). Slides were covered and denatured for 3&#x000a0;min at 80&#x000a0;&#x000b0;C, followed by an incubation step for 2&#x000a0;h in a humidified chamber at room temperature. After two 15&#x000a0;min washes with wash buffer (70&#x000a0;% formamide, 10&#x000a0;mM Tris pH&#x000a0;7.2, 0.1&#x000a0;% BSA), slides were washed with TBS-T and PBS, each twice for 5&#x000a0;min. Neurons were counterstained with Cy5-Neuron N dye. Afterwards, slides were dehydrated through an ethanol series and air dried. Slides were covered using VECTASHIELD. Antifade Mounting Medium with DAPI (Vector Laboratories). Neuronal cells were counterstained with Deep-Red fluorescent Nissl stain dye (Neuro Trace 640/660, ThermoFisher).</p><p>For analysis, 50 sections of the brainstem were captured using a 100 x objective and 100 nuclei were analyzed for their telomeric length, using TFL-Telo V1.0 software [<xref ref-type="bibr" rid="CR49">49</xref>]. Five mice per group were analyzed for telomere length.</p></sec><sec id="Sec9"><title>Immunohistochemical analysis of brain tissue</title><p>Brain from transgenic mice and appropriate controls were halved and fixed in 4&#x000a0;% para-formaldehyde and embedded in paraffin. Five micrometer sections were cut longitudinally and after deparaffinization and rehydration, sections were boiled in 0.01&#x000a0;M citrate buffer pH&#x000a0;6.0 for 5&#x000a0;min. Blocking was performed in TBS-T with 1&#x000a0;% BSA. Slides were incubated with antibody overnight in PBS-T&#x02009;+&#x02009;1&#x000a0;% BSA (1:1000, anti-Iba-1 (Wako 019-19741) and anti-&#x003b1;-synuclein (phospho S129) antibody (Abcam, ab51253)) at 4&#x000a0;&#x000b0;C. After three washes in PBS for 5&#x000a0;min, the sections were incubated with fluorescence labeled secondary antibodies for 90&#x000a0;min (anti-rabbit, Cy3, 1:2000, anti-mouse, Cy3 1:2000). Analysis was performed using a fluorescence microscope. For microglia analysis ten sections from brainstem were analyzed. For phospho-&#x003b1;-synuclein images were captured of the brainstem, cerebellum and deep mesencephalic nucleus.</p></sec><sec id="Sec10"><title>Quantification of p-asyn staining</title><p>Quantification of p-asynuclein staining was performed using ImageJ. Image acquisition was performed with 20x of magnification. Seven pictures were taken per mouse with a distance of 0.2&#x000a0;&#x003bc;m in the region of the deep mesencephalic nucleus. Microscopy data were processed and analysed using ImageJ64 1.49 software and a Macro written for ImageJ. First step of the macro was to substract the background colour of the picture and convert it into black and white. Second step was the measurement of the stained area (black), using the tool &#x0201c;analyze particles&#x0201d;. An automated threshold has been used which detected a minimum of 12 and the highest 255 particles.</p></sec><sec id="Sec11"><title>Quantitative real-time PCR analyses</title><p>A piece of brainstem was cut from the brain hemispheres were snap frozen in liquid nitrogen and stored at &#x02212;80&#x000a0;&#x000b0;C until use. A piece of brainstem was cut. Disruption and homogenization of the tissue was done using the TissueLyser (Qiagen). RNA was isolated with the RNeasy lipid tissue kit (Qiagen) according to the manufacturer&#x02019;s protocol. cDNA synthesis was done from total RNA using the GoScript<sup>TM</sup> Reverse Transcription System (Promega). Quantitative real-time PCR analysis was done with the Absolute qPCR ROX Mix (Thermo Scientific) and the Universal Probe Library (Roche) on an ABI7300 Real-Time PCR System (Applied Biosystems). Brainstems from Terc<sup>+/+</sup> mice were used as a reference. Primers were generated intron-spanning and primer sequences are mentioned in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2.</p></sec><sec id="Sec12"><title>Morphometric analysis of reconstructed microglia</title><p>IF stained sections were analyzed by confocal laser scanning microscopy using a ZEISS LSM 510 META. High magnification and z-stack images were obtained using a LD LCI Plan-Apochromat 25x/0.8 Imm. Korr. DIC objective (Zeiss). Imaging speed was 4 (pixel dwell 12.8&#x000a0;&#x003bc;s) with a resolution of 1024x1024 pixels. For 3D-volumes to analyze microglia morphology a z-stack of 30&#x000a0;&#x003bc;m thickness with an interval of 0.8&#x000a0;&#x003bc;m was used.</p><p>Three-dimensional (3D)-reconstructions were performed using IMARIS Filament Tracer (<ext-link ext-link-type="uri" xlink:href="http://www.bitplane.com">www.bitplane.com</ext-link>), as previously described [<xref ref-type="bibr" rid="CR23">23</xref>]. The z-stack was uploaded to the IMARIS-program rendering a 3D volume. Cells were reconstructed from the inferior molecular layer. Tracing was performed in a region of interest comprising only one cell. Cells were appropriate for the analysis when the staining was distinct and the whole cell including all processes was visible in the 3D volume. The automatic detection mode was applied. Parameters were: no loops allowed, start and end points calculated via spot detection. The parameters total process length, total volume, number of branch points, number of segments, number of terminal points and were analyzed. An automated Sholl analysis was also performed on each digitized cell with the IMARIS software using spheres whose radii were increasing by 1&#x000a0;&#x003bc;m per step. Five Iba1-positive microglia per animal/section were reconstructed and analyzed, and 4&#x02013;5 animals were included in each group.</p></sec><sec id="Sec13"><title>Isolation of microglia from brainstem</title><p>Microglia were acutely FACS-isolated from the brain stem as described previously using CD45 and CD11b antibodies [<xref ref-type="bibr" rid="CR50">50</xref>]. RNA was extracted from the acutely isolated microglia and using the RNeasyMicro kit (Qiagen) according to the manufacturer&#x02019;s protocol isolated using Qiagen RNeasy.</p></sec><sec id="Sec14"><title>RNA sequencing and bioinformatics</title><p>RNA quality was determined by the Experion&#x02122; Automated Electrophoresis System, and samples with a minimum RIN quality score of minimally seven were used. The sequence libraries were prepared with the Illumina Truseq RNA sample preparation, and 50&#x000a0;bp single read sequencing was performed on the Illumina Hiseq 2500 platform. Reads were aligned using the Star 2.3.1&#x000a0;l aligner [<xref ref-type="bibr" rid="CR51">51</xref>] to the ensemble reference, in which two mismatches were allowed. The aligned reads were sorted by Samtools version 0.1.19 [<xref ref-type="bibr" rid="CR52">52</xref>] and quantified by HT-seq count 0.5.4 [<xref ref-type="bibr" rid="CR53">53</xref>]. Data was analyzed using BioConductor packages and R, with particular importance of EdgeR [<xref ref-type="bibr" rid="CR54">54</xref>]. Heatmaps were generated with heatmap2 function of package gplots. Gene enrichment and annotation analyses were performed using DAVID [<xref ref-type="bibr" rid="CR55">55</xref>] and Ingenuity pathway analysis (IPA).</p></sec><sec id="Sec15"><title>Statistical analysis</title><p>Differences between groups in the experiments were evaluated for statistical significance by using the Mann-Whitney <italic>U</italic> test (for parameters measured at discrete time-points, non-parametric test) or the Log-rank Mantel-Cox test (Kaplan-Meier curves). Differences with P values of less than 0.05 were considered significant. Statistical analysis of beamwalk were performed using the 2-way anova test. Analyses were conducted using the GraphPad Prism software, version 5.04.</p></sec></sec><sec id="Sec16"><title>Results</title><sec id="Sec17"><title>Telomere shortening reduces the life span of &#x003b1;<italic>-</italic>synuclein transgenic mice</title><p>In order to investigate the effects of ageing in the Parkinson&#x02019;s disease mouse model, Thy-1&#x000a0;h[A30P] &#x003b1;&#x02013;synuclein transgenic mice (&#x003b1;SYN<sup>tg/tg</sup>) were crossed with Terc knockout mice (Terc<sup>-/-</sup>). For the final study cohorts, the 3rd generation Terc<sup>-/-</sup> mice with short telomeres were generated (G3Terc<sup>-/-</sup>), with or without the human mutated [A30P] &#x003b1;&#x02013;synuclein transgene (&#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> and G3Terc<sup>-/-</sup> Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Figure S1A). Mice with wild type Terc were used as controls (&#x003b1;SYN<sup>tg/tg</sup> and Terc<sup>+/+</sup>; Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Figure S1A). Cohorts of 75&#x000a0;weeks old G3Terc<sup>-/-</sup> animals showed a significant, age-dependent reduction in telomere length in the brainstem (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Figure S1B). &#x003b1;SYN<sup>tg/tg</sup> mice are known to develop an obvious motoric phenotype at 80&#x02013;85&#x000a0;weeks of age, which first affects hind limb mobility, showing a weakening of extremities and influence on the locomotor performance [<xref ref-type="bibr" rid="CR47">47</xref>]. This motoric phenotype occurs due to the loss of neurons and Lewi body-like inclusions in the different compartments of the brain [<xref ref-type="bibr" rid="CR42">42</xref>]. Telomere dysfunction led to a dramatic reduction of life span. &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> animals died significantly earlier with a median life span of 73.6&#x000a0;weeks, whereas &#x003b1;SYN<sup>tg/tg</sup> animals survived with a median of 85.6&#x000a0;weeks (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, Log-rank (Mantel-Cox) Test).<fig id="Fig1"><label>Fig. 1</label><caption><p>Telomere shortening shortens lifespan of &#x003b1;SYN transgenic mice and increases aggregate formation. <bold>a</bold> Kaplan Meier survival curves for &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> (<italic>n</italic>&#x02009;=&#x02009;34), &#x003b1;SYN<sup>tg/tg</sup> (<italic>n</italic>&#x02009;=&#x02009;36), G3Terc<sup>-/-</sup> (<italic>n</italic>&#x02009;=&#x02009;31) and Terc<sup>+/+</sup> mice (<italic>n</italic>&#x02009;=&#x02009;21). &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice show a significant decrease in survival (median life span: 73.6&#x000a0;weeks) in comparison to the &#x003b1;SYN<sup>tg/tg</sup> mice (median life span 85.6&#x000a0;weeks; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) and the G3Terc<sup>-/-</sup> mice (median life span 90&#x000a0;weeks; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001). <bold>b</bold> Analysis of the pathological &#x003b1;-synuclein phosphorylation (p-&#x003b1;syn). The amount of the p-&#x003b1;syn used as a marker of disease severity. To characterize the severity and the affected zone, a scoring system was used (see Additional file <xref rid="MOESM3" ref-type="media">3</xref>: Figure S2). Stainings were repeated and evaluated three times and the mean values of the scores were used. &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice (75&#x000a0;weeks old with a motoric phenotype) showed significantly more p-&#x003b1;syn staining than age-matched &#x003b1;SYN<sup>tg/tg</sup> mice (75&#x000a0;weeks old, no phenotype, <italic>p</italic>&#x02009;=&#x02009;0.0064). <bold>c</bold> Quantification of p-asynuclein staining in the region of deep Mesencephalic nucleus. Seven sections of the region were taken and quantified using ImageJ. &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice show significant higher p-asynuclein staining in comparison to age matched &#x003b1;SYN<sup>tg/tg</sup> mice (<italic>P</italic>&#x02009;=&#x02009;0.0043). <bold>d</bold> Classification of Proteinase K resistant &#x003b1;-synuclein aggregates. &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice showed stronger aggregate formation compared to &#x003b1;SYN<sup>tg/tg</sup> mice (75&#x000a0;weeks old, no phenotype, <italic>p</italic>&#x02009;=&#x02009;0.0006). 85&#x000a0;weeks old &#x003b1;SYN<sup>tg/tg</sup> mice with terminal phenotype showed a very dense pattern of p-&#x003b1;syn positive aggregates (&#x003b1;SYN<sup>tg/tg</sup> 75&#x000a0;weeks vs. &#x003b1;SYN<sup>tg/tg</sup>85&#x000a0;weeks; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001). <bold>e</bold> Representative pictures of membranes, where whole brain hemispheres were attached and digested with Proteinase K. Proteinase K resistant &#x003b1;-synuclein aggregates reflect the severity of disease</p></caption><graphic xlink:href="40478_2016_364_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec18"><title>Telomere shortening is associated with progression of the disease-related aggregate formation in Thy-1 [A30P] &#x003b1;<italic>-</italic>synuclein transgenic mice</title><p>&#x003b1;&#x02013;Synuclein is located in the presynaptic neurons and accumulated with progressive disease. After undergoing posttranslational modification, phosphorylation of &#x003b1;&#x02013;synuclein at serine129 serves as a disease progression marker [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. In order to investigate whether the earlier onset of synucleinopathy in &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> animals was due to accelerated aggregate accumulation, phosphorylated &#x003b1;-synuclein on Serin129 was analyzed by phospho-&#x003b1;&#x02013;synuclein staining and aggregate formation measured using PK-PET Blot. Accordingly, the 75&#x000a0;weeks old &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> animals showing a motoric phenotype were compared with 75&#x000a0;weeks old &#x003b1;SYN<sup>tg/tg</sup> animals without phenotype as well as with phenotypic &#x003b1;SYN<sup>tg/tg</sup> mice with a median age of 85&#x000a0;weeks. Comparison was done using a score as shown in Additional file <xref rid="MOESM3" ref-type="media">3</xref>: Figure S2.</p><p>Analysis of the brainstem revealed a significantly higher amount of phosphorylated &#x003b1;-synuclein in &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice compared to the aged-matched group of &#x003b1;SYN<sup>tg/tg</sup> mice (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b-e</xref> and Additional file <xref rid="MOESM3" ref-type="media">3</xref>: Figure S2A, <italic>P</italic>&#x02009;=&#x02009;0.0064). Eighty-fiveweeks old &#x003b1;SYN<sup>tg/tg</sup> mice showed an increase in phosphorylated &#x003b1;-synuclein (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001, Additional file <xref rid="MOESM3" ref-type="media">3</xref>: Figure S2A). Quantification of p-asyn staining in deep mesencephalic nucleus using ImageJ showed significant differences between &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> animals 75&#x000a0;weeks old &#x003b1;SYN<sup>tg/tg</sup> (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>, <italic>P</italic>&#x02009;=&#x02009;0.0043).</p><p>Thus, telomerase dysfunctional &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice at 75&#x000a0;weeks showed an increased aggregate formation in comparison to the age-matched &#x003b1;SYN<sup>tg/tg</sup> mice, and 85&#x000a0;weeks old &#x003b1;SYN<sup>tg/tg</sup> mice displayed the highest aggregate formation. Similar observations were made with the classification of PK digested &#x003b1;-synuclein, whereas &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice compared to the aged-matched group of &#x003b1;SYN<sup>tg/tg</sup> mice showed significant higher levels of proteinase K resistant aggregates (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1d</xref>, &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> vs. &#x003b1;SYN<sup>tg/tg</sup> Terc<sup>+/+</sup>; <italic>P</italic>&#x02009;=&#x02009;0.0006 &#x00026; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1e</xref>). Definition of the score, which was used to assess proteinase K digested aggregates is shown in Additional file <xref rid="MOESM3" ref-type="media">3</xref>: Figure S2B.</p></sec><sec id="Sec19"><title>Telomere shortening deteriorates motor balance and coordination in Thy-1 [A30P] &#x003b1;<italic>-</italic>synuclein transgenic mice</title><p>As previously described, &#x003b1;SYN<sup>tg/tg</sup> transgenic mice develop a progressive loss of motor balance, correlating with the accumulation of aggregates [<xref ref-type="bibr" rid="CR43">43</xref>]. To determine the influence of telomere dysfunction on motor balance, general balance and coordination, 72&#x000a0;weeks old mice from the different cohorts were compared using the beamwalk test. This test is used to assess the motor phenotype in mouse models [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. We analyzed the number of paw slips and the time which was needed to traverse over beams of different sizes and shapes (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref> -<xref rid="Fig2" ref-type="fig">e</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Behavioural characterization of &#x003b1;SYN<sup>tg/tg</sup> transgenic mice in the context of telomere shortening. Behavioral experiments were performed before the occurrence of a motoric phenotype. All mice were tested at an age of 72&#x000a0;weeks (<italic>n</italic>&#x02009;=&#x02009;7&#x02013;10). <bold>a</bold>-<bold>d</bold> Beamwalk: Mice were trained for three consecutive days to walk over a wooden beam. The test was performed with different beam diameters and shapes (square or round). Graphs show the latency to walk over a beam with a square diameter of <bold>a</bold> 28&#x000a0;mm (&#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice vs. &#x003b1;SYN<sup>tg/tg</sup>; <italic>p</italic>&#x02009;=&#x02009;0.0095), <bold>b</bold> 12&#x000a0;mm (&#x003b1;SYN<sup>tg/tg</sup>G3Terc<sup>-/-</sup> mice vs. &#x003b1;SYN<sup>tg/tg</sup>; <italic>p</italic>&#x02009;=&#x02009;0.0023) or a round beam with a diameter of <bold>c</bold> 28&#x000a0;mm (&#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice vs. &#x003b1;SYN<sup>tg/tg</sup>; <italic>p</italic>&#x02009;=&#x02009;0.0095), and <bold>d</bold> 17&#x000a0;mm (&#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice vs. &#x003b1;SYN<sup>tg/tg</sup>; <italic>p</italic>&#x02009;=&#x02009;0.003). &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice showed a reduced latency to cross the different beams. <bold>e</bold> Number of footslips. &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice show a significant increase in the number of footslips in comparison to &#x003b1;SYN<sup>tg/tg</sup> mice (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001; 2-way Anova)</p></caption><graphic xlink:href="40478_2016_364_Fig2_HTML" id="MO2"/></fig></p><p>&#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice required more time to cross the beam than &#x003b1;SYN<sup>tg/tg</sup> mice (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>), which was observed for all four beam types tested (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a-d</xref>). The absolute number of foot slips while crossing the beam, was counted over all walks. &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice showed a significant increase in the number of footslips compared to &#x003b1;SYN<sup>tg/tg</sup> mice (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2e</xref>; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001, 2-way Anova). Furthermore, exploratory behavior, especially the activity and the duration in different zones of the open field showed no significant difference between the different groups (Additional file <xref rid="MOESM4" ref-type="media">4</xref>: Figure S3A &#x00026; B), in line with previous data showing that the &#x003b1;-synuclein phenotype declines cognitive effects and coordination [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR59">59</xref>], but not exploratory and anxiety-related behavior of the animals. Also, the forepaw grip capacity using the string agility test did not reveal any significant differences at the time of the experiment (Additional file <xref rid="MOESM4" ref-type="media">4</xref>: Figure S3C).</p></sec><sec id="Sec20"><title>Telomere shortening is associated with a decline in activation of microglia in brainstem</title><p>Microgliosis is a well-known process in brain pathology and has been described in all animal models of PD [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>] and in PD patients [<xref ref-type="bibr" rid="CR62">62</xref>]. We therefore examined the expression of the microglia marker Iba-1 in our various mouse cohorts. While no significant differences in Iba-1 immunoreactivity were found in mice without phenotypic synucleinopathy, the 75&#x000a0;week old &#x003b1;SYN<sup>tg/tg</sup>, 85&#x000a0;week old Terc<sup>+/+</sup> animals and 85&#x000a0;week old G3Terc<sup>-/-</sup> all displayed similar number of Iba1 positive cells (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>). The presence of behavioral phenotypes were accompanied by an induction of Iba-1 immunoreactivity in both 75&#x000a0;week old &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> and 85&#x000a0;week old &#x003b1;SYN<sup>tg/tg</sup>animals (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>; <italic>P</italic>&#x02009;=&#x02009;0.0058 and Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>). Interestingly, Iba-1 immunoreactivity was significantly higher in 85&#x000a0;weeks old &#x003b1;SYN<sup>tg/tg</sup> with phenotype compared to 75&#x000a0;week old &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice with phenotype (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>; <italic>P</italic>&#x02009;=&#x02009;0.0072). These results support the hypothesis that telomere erosion/shortening may lead to an impaired microglia response.<fig id="Fig3"><label>Fig. 3</label><caption><p>Activation of microglia and astrocytes in the brainstem. <bold>a</bold> The histogram represents the number of Iba-1 positive microglia in the brainstem (<italic>n</italic>&#x02009;=&#x02009;5&#x02013;6 mice per group, ten pictures were counted per mouse). Note that aged-matched &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice (average 22.47&#x02009;&#x000b1;&#x02009;2.32, <italic>n</italic>&#x02009;=&#x02009;6) and &#x003b1;SYN<sup>tg/tg</sup> mice (average 13.00&#x02009;&#x000b1;&#x02009;0.67, <italic>n</italic>&#x02009;=&#x02009;5) show a significant difference in number of microglia (<italic>p</italic>&#x02009;=&#x02009;0.0058). <bold>b</bold> Representative pictures of Iba-1 staining in brainstem</p></caption><graphic xlink:href="40478_2016_364_Fig3_HTML" id="MO3"/></fig></p><p>To further address and confirm the differences in microglia response a detailed 3D morphological analysis was performed. For this purpose only microglia in the dorsal part of the medullary reticular nucleus (MDRNd) of the brain stem were analyzed to exclude potential morphological differences due to the brain region (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref>). Representative pictures of single cells from 75&#x000a0;week old &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice and 85&#x000a0;week old wild type animals (Terc<sup>+/+</sup>), G3Terc<sup>-/-</sup> and &#x003b1;SYN<sup>tg/tg</sup> revealed a significant morphological microglia response in 85&#x000a0;week old &#x003b1;SYN<sup>tg/tg</sup> only (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4b</xref>). In all other mice, microglia displayed a more ramified morphology reminiscent of a non-reactive microglia phenotype (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4b</xref>). This was confirmed by quantitative morphometric analysis for total process length, volume of processes, number of process branch points, number of process segments, number of terminal process branches and number of Sholl intersections (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4c</xref>, Additional file <xref rid="MOESM5" ref-type="media">5</xref>: Figure S4 for methodological details). All these readouts confirm that only microglia in symptomatic, 85&#x000a0;week old &#x003b1;SYN<sup>tg/tg</sup> animals significantly changed their morphology. Interestingly, this morphological transition was not observed in affected 75&#x000a0;week old &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice, furthermore suggesting that telomere attrition impaired the microglia response in the presence of PD pathology (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4c</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><p>3D reconstruction of brainstem microglia and their morphometric analysis. <bold>a</bold> Coronal section through the medulla outlining the region from which Iba1-positive microglia were selected for 3D morphometric analysis (<italic>arrow</italic>, right; <italic>broken red line</italic>, left) MDRN: Medullary reticular nucleus, dorsal part. Image reproduced from the Allen Brain Atlas. <bold>b</bold> Representative 3D-reconstructed microglia from aged WT (Terc<sup>+/+</sup>), G3Terc<sup>-/-</sup>, &#x003b1;SYN<sup>tg/tg</sup> mice and &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice. <bold>c</bold> Morphometric analyses of reconstructed microglia. Six different parameters relating to process length and branching were analysed using Imaris Bitplane software. For a more detailed description of the measurement characteristics, see Additional file <xref rid="MOESM5" ref-type="media">5</xref>: Figure S4. Five Iba1-positive microglia per animal were reconstructed and analyzed, and 4&#x02013;5 animals were included in each group. Mean group values&#x02009;+&#x02009;SEM are depicted. A one-way ANOVA with a post-hoc LSD test was applied to determine significant differences between groups. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05. <bold>b</bold> Scale Bar&#x02009;=&#x02009;10&#x000a0;&#x003bc;m</p></caption><graphic xlink:href="40478_2016_364_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec21"><title>Telomere shortening is linked to a reduced expression of inflammatory genes</title><p>The lack of a morphological response of microglia in diseased mice with short telomeres prompted the question whether the inflammatory response in &#x003b1;-synuclein transgenic mice with and without telomerase function was different. We therefore compared the mRNA expression of different inflammatory markers and chemokines in whole brainstem RNA of the different subgroups (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). For normalization, the house keeping gene was subtracted and the Terc<sup>+/+</sup> group were set to 100&#x000a0;%. The pro-inflammatory cytokine IL-1&#x000df; was upregulated in 75 and 85&#x000a0;weeks old &#x003b1;SYN<sup>tg/tg</sup> mice irrespective of the presence of disease symptoms. However, this cytokine was significantly lower expressed in &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> compared to &#x003b1;SYN<sup>tg/tg</sup> mice (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5a</xref>; <italic>p</italic>&#x02009;=&#x02009;0.0147)). Other central inflammatory markers like TNF&#x003b1; or TGF&#x000df; were highly elevated in 85&#x000a0;weeks old &#x003b1;SYN<sup>tg/tg</sup> mice with a clear phenotype, but this increase was not detected in &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice with phenotype (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5a-c</xref>). Similar expression patterns were observed for <italic>CD14, MHCII, CXCR1</italic>, and <italic>CXCL10</italic> (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5d</xref> -<xref rid="Fig5" ref-type="fig">h</xref>). Iba-1 RNA expression levels confirmed that symptomatic &#x003b1;SYN<sup>tg/tg</sup> 85&#x000a0;week old animals had the highest expression level of Iba-1 (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5i</xref>: &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> compared to &#x003b1;SYN<sup>tg/tg</sup> 85&#x000a0;weeks; <italic>P</italic>&#x02009;=&#x02009;0.0202). The data suggested an inflammatory reaction in symptomatic &#x003b1;SYN<sup>tg/tg</sup> 85-week-old animals which was impaired in Terc-deficient animals.<fig id="Fig5"><label>Fig. 5</label><caption><p>Expression level of inflammatory markers. RT-PCR was performed on the inflammatory markers <bold>a</bold> Il1&#x000df; (&#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice vs. &#x003b1;SYN<sup>tg/tg</sup>; <italic>p</italic>&#x02009;=&#x02009;0.0147), <bold>b</bold> TNF&#x003b1; and <bold>c</bold> TGF&#x000df;. Inflammation-induced activation of monocytes was shown with CD14 (<bold>d</bold>), MHC2 (<bold>e</bold>) and CXCR1 (<bold>f</bold>). Monocyte activation was analyzed with CD80 (<bold>g</bold>) and Interferon &#x003b3; induced protein CXCL10 (<bold>h</bold>). <bold>i</bold> Iba1 was clearly reduced in &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice (&#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice vs. &#x003b1;SYN<sup>tg/tg</sup>; <italic>p</italic>&#x02009;=&#x02009;0.0202). After substracting of the housekeeping gene all different groups were normalized to the average ct of the Terc<sup>+/+</sup> group</p></caption><graphic xlink:href="40478_2016_364_Fig5_HTML" id="MO5"/></fig></p><p>Similarly, reactive astrocytes (determined by staining for glial fibrillary acidic protein (GFAP) were significantly increased in phenotypic &#x003b1;SYN<sup>tg/tg</sup> animals at 85&#x000a0;weeks of age and with distinct phenotype (Additional file <xref rid="MOESM4" ref-type="media">4</xref>: Figure S3D). Mice with short telomeres at their final stage of disease show reduced astrocyte activation in comparison to &#x003b1;SYN<sup>tg/tg</sup> with disease (Additional file <xref rid="MOESM4" ref-type="media">4</xref>: Figure S3D).</p></sec><sec id="Sec22"><title>RNA-sequencing analysis of brain stem microglia indicate partially opposing gene expression programs</title><p>To determine how telomere erosion affected microglia gene expression in &#x003b1;Syn<sup>tg/tg</sup> mice, brainstem microglia were FACS sorted from &#x003b1;Syn<sup>tg/tg</sup> and &#x003b1;Syn<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice, and gene expression levels were quantified using RNA sequencing.</p><p>Multidimensional scaling analysis showed clustering of samples in a genotype- and phenotype dependent manner (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6a</xref>). Microglia samples from control mice and unaffected &#x003b1;SYN<sup>tg/tg</sup> mice clustered closely together. Microglia samples from diseased &#x003b1;SYN<sup>tg/tg</sup> mice clustered most distant from all other samples. Interestingly, the samples isolated from affected &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice clustered separately but closer to control microglia than &#x003b1;SYN<sup>tg/tg</sup> samples.<fig id="Fig6"><label>Fig. 6</label><caption><p>RNA sequencing analysis of microglia. <bold>a</bold> Multidimensional scaling plot of microglia RNAseq data from different mice. &#x003b1;SYN<sup>tg/tg</sup> microglia from mice with a phenotype cluster separately from all other microglia samples and are most similar to &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> microglia. Gene expression in control and &#x003b1;SYN<sup>tg/tg</sup> microglia without a phenotype are very similar and form a separate, mixed cluster. <bold>b</bold> Volcano plots showing the significantly differentially expressed genes between pairs of conditions. <italic>Dark red dots</italic>: FDR&#x02009;&#x0003c;0.05 and logFC&#x02009;&#x0003e;1 and <italic>bright red dots</italic>: FDR&#x02009;&#x0003c;0.0001 and logFC&#x02009;&#x0003e;3. <bold>c</bold> The number of differentially expressed genes (up, down and total) between the compared groups. <bold>d</bold> Heatmap visualization of genes differentially expressed between &#x003b1;SYN<sup>tg/tg</sup> and &#x003b1;SYN<sup>tg/tg</sup> G3Terc samples (FDR &#x0003c;0.001, logFC&#x02009;&#x0003e;3)</p></caption><graphic xlink:href="40478_2016_364_Fig6_HTML" id="MO6"/></fig></p><p>Gene expression profiles were analyzed and pair-wise comparisons were plotted, with dark red: FDR&#x02009;&#x0003c;0.05 and logFC&#x02009;&#x0003e;1 and bright red: FDR&#x02009;&#x0003c;0.0001 and logFC&#x02009;&#x0003e;3 as criteria (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6b</xref>). The gene expression profiles of control and unaffected &#x003b1;SYN<sup>tg/tg</sup> microglia were almost indistinguishable; only 2 genes were differentially expressed between control and unaffected &#x003b1;SYN<sup>tg/tg</sup> microglia (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6b</xref>, common criteria FDR&#x02009;&#x0003c;0.05 and logFC&#x02009;&#x0003e;1). Gene expression in microglia isolated from &#x003b1;SYN<sup>tg/tg</sup> mice that displayed disease phenotype (&#x003b1;SYN<sup>tg/tg</sup> phenotype) was very different from control microglia with 834 genes were differentially expressed (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6c</xref>). An intermediate gene expression profile was observed in &#x003b1;SYN<sup>tg/tg</sup>G3Terc<sup>-/-</sup> mice with 557 genes were differentially expressed between &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> and control microglia (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6c</xref>). These data indicate that microglia in diseased &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> behave differently in terms of gene expression changes in gene expression compared to affected &#x003b1;SYN<sup>tg/tg</sup> microglia with regard to &#x003b1;syn-induced pathology. Comparison of &#x003b1;SYN<sup>tg/tg</sup> and &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> microglia expression profiles showed that 423 genes were differentially expressed between these samples and that most of these genes (329) had an increased expression in &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> microglia (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6c</xref>), suggesting that the lack of telomerase function had a significant influence on the microglia response to &#x003b1;-synuclein pathology. The number of differentially expressed genes between the compared samples and if they are up- or down-regulated is indicated in Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6c</xref>.</p><p>To visualize differences in gene expression between control, unaffected and affected &#x003b1;SYN<sup>tg/tg</sup>, and &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup>mice, a heat map of the most significantly (FDR &#x0003c;1E-3, logFC&#x02009;&#x0003e;3) differentially expressed genes between these samples was generated (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6d</xref>). Many of the genes upregulated in both SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> and &#x003b1;SYN<sup>tg/tg</sup> microglia were more abundantly expressed in &#x003b1;SYN<sup>tg/tg</sup> microglia. Besides genes that were similarly up- or down-regulated in both data sets, several genes were antagonistically expressed between &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> and &#x003b1;SYN<sup>tg/tg</sup> microglia with many genes that were down-regulated in expression in &#x003b1;SYN<sup>tg/tg</sup> microglia showed an increased expression in &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> microglia. MMP8, MMP, CXCR2, IL1R1, S100A and S100B were downregulated in &#x003b1;SYN<sup>tg/tg</sup> microglia and upregulated in &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> microglia.</p><p>Next, Ingenuity Pathway Analysis (IPA) was used for enrichment analyses of genes with increased in expression in both &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> and &#x003b1;SYN<sup>tg/tg</sup> samples and of genes with increased expression in &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> compared to &#x003b1;SYN<sup>tg/tg</sup> microglia to identify pathways that were overrepresented in these gene lists (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). There were several pathways similarly regulated in both &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> and &#x003b1;SYN<sup>tg/tg</sup> samples, for example Granulocyte Adhesion and Diapedesis or Atherosclerosis Signaling (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). However, prominent differences concerning predicted pathways activity were also observed between &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> and &#x003b1;SYN<sup>tg/tg</sup> samples. As shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> LXR/RXR activation was significantly enriched in the downregulated profile in &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> but significantly up-regulated in &#x003b1;SYN<sup>tg/tg</sup> samples. Both cAMP-mediated signaling and acute phase response signaling were significantly inhibited in &#x003b1;SYN<sup>tg/tg</sup> samples only, whereas cell cycle events were only significantly inhibited only in &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> microglia. These cells significantly upregulated the pathway for nitric oxide and reactive oxygen species production, whereas no such response was found in &#x003b1;SYN<sup>tg/tg</sup> samples. Significantly changed IL-10 signaling was only found in &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> microglia, whereas &#x003b1;SYN<sup>tg/tg</sup> samples showed significant changes in G-protein coupled receptor signaling. However, the data of the latter two did not allow drawing conclusions about the direction of these changes.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Changes in IPA canonical pathways in brainstem microglia</p></caption><table frame="hsides" rules="groups"><thead><tr><th>IPA canonical pathway</th><th>&#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup>vs. controls (<italic>p</italic> value)</th><th>Predicted activity pattern (z score)</th><th>&#x003b1;SYN<sup>tg/tg</sup> vs controls (<italic>p</italic> value)</th><th>Predicted activity pattern (z score)</th></tr></thead><tbody><tr><td>Granulocyte Adhesion and Diapedesis</td><td>5,75E-08</td><td>NA</td><td>2,34E-09</td><td>NA</td></tr><tr><td>Atherosclerosis Signaling</td><td>7,76E-07</td><td>NA</td><td>4,27E-07</td><td>NA</td></tr><tr><td>LXR/RXR Activation</td><td>8,51E-08</td><td>Inhibition-0,277</td><td>9,55E-09</td><td>Activation 2,5</td></tr><tr><td>cAMP-mediated signaling</td><td>ns</td><td>NA</td><td>7,59E-06</td><td>Inhibition-0,688</td></tr><tr><td>Acute Phase Response Signaling</td><td>ns</td><td>NA</td><td>0,000104713</td><td>Inhibition-0,535</td></tr><tr><td>Cell Cycle: G2/M DNA Damage Checkpoint Regulation</td><td>3,89E-05</td><td>Inhibition-0,378</td><td>ns</td><td>NA</td></tr><tr><td>Production of Nitric Oxide and Reactive Oxygen Species in Macrophages</td><td>1,02E-05</td><td>Activation 2,496</td><td>ns</td><td>NA</td></tr><tr><td>IL-10 Signaling</td><td>4,57E-05</td><td>NA</td><td>ns</td><td>NA</td></tr><tr><td>G-Protein Coupled Receptor Signaling</td><td>ns</td><td>NA</td><td>8,51E-06</td><td>NA</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec23"><title>Discussion</title><p>We here show that telomere shortening correlated to an accelerated phenotype and early death in our Parkinson mouse model. Moreover, our data suggest that telomere shortening inhibited a potentially protective inflammatory microglia response with respect to &#x003b1;Syn pathology. The present study adds up to an ongoing discussion that telomeres and telomere erosion may play a pivotal role in Parkinson&#x02019;s disease.</p><p>It is very well known that microglia are activated in all synucleopathies including humans with PD [<xref ref-type="bibr" rid="CR62">62</xref>&#x02013;<xref ref-type="bibr" rid="CR64">64</xref>]. Numerous reports have described the expression of pro-inflammatory cytokines in microglia in PD pathology. It has been described that &#x003b1;Syn itself is a powerful inducer of microglial IL-1&#x003b2; expression and release, which includes TLR2 signaling and NLRP3 inflammasome activity [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. Usually, this pro-inflammatory function of microglia is suggested to actively contribute to PD pathology [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>] and microglia have often been discussed being detrimental elements in PD [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>].</p><p>The data presented here clearly confirm the pro-inflammatory response of wild type microglia in the presence of &#x003b1;Syn pathology. Microglia in the &#x003b1;SYN<sup>tg/tg</sup> model showed the classical morphological signs of activation such as retraction of processes and we furthermore detected changes in mRNA of several pro-inflammatory markers in the brain stem of these mice. Surprisingly, immunohistochemical analysis of Iba1 expression and a detailed analysis of microglia morphology suggested that microglia with short telomeres displayed an impaired response in the presence of &#x003b1;Syn pathology in our &#x003b1;SYN<sup>tg/tg</sup> model of PD. This impaired microglia response was furthermore supported by qPCR investigations as none of the investigated pro-inflammatory markers was increased in the brainstem of &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> animals. In addition to the impaired inflammatory microglia response, &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> animals showed accelerated disease progression and a significantly reduced life span. Our data suggest that the microglia response in the &#x003b1;SYN<sup>tg/tg</sup> model of PD may not be solely detrimental, but may also have protective elements inhibiting disease progression and early death.</p><p>Indeed it was described that microglia showed an enhanced phagocytic activity when treated with monomeric &#x003b1;Syn [<xref ref-type="bibr" rid="CR68">68</xref>]. Microglial cells were capable of fast &#x003b1;Syn degradation with an intracellular &#x003b1;Syn half-life of about 4&#x000a0;h, which is about half of the degradation time for &#x003b1;Syn in astrocytes and neurons [<xref ref-type="bibr" rid="CR71">71</xref>]. Regarding microglial phagocytosis of &#x003b1;Syn, Toll-like receptors (TLRs) seem to play an important part in recognition and internalisation of &#x003b1;Syn via TLR activity [<xref ref-type="bibr" rid="CR71">71</xref>]. Accordingly, it was demonstrated recently that TLR4 ablation leads to a disturbed clearance of &#x003b1;Syn by microglia [<xref ref-type="bibr" rid="CR72">72</xref>]. Thus, microglia were important factors in the clearance of toxic &#x003b1;Syn in the brain. Our observation that in the brains of &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> animals &#x003b1;Syn pathology was significantly increased when microglia response was impaired would corroborate this notion.</p><p>Why microglia in &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> animals failed to morphologically react to abundantly present &#x003b1;Syn in the brain is unclear at the moment. Our gene expression analysis did not show differences between G3Terc<sup>-/-</sup> and wild type microglia suggesting that lack of telomerase activity and telomere shortening did not have a major impact on microglia gene expression pattern in general. Similarly, when comparing the response of microglia with and without telomere attrition to peripheral LPS injections, no differences were observed, suggesting that microglia in G3Terc<sup>-/-</sup> animals are not generally impaired in their inflammatory reactivity [<xref ref-type="bibr" rid="CR73">73</xref>].</p><p>To understand the molecular responses of microglia with long and short telomeres to the presence of &#x003b1;Syn pathology we subjected brain stem microglia to RNAseq and bioinformatical analysis. These data revealed that the reaction of microglia in &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> animals was not blunted. Thus despite no obvious changes in morphology, &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> microglia did show changes in gene expression. Microglia in &#x003b1;SYN<sup>tg/tg</sup>animals with phenotype up- and down-regulated 505 and 329 genes compared to controls, respectively. Microglia in &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> animals with phenotype showed less changes, as these cells up-regulated 472 genes but only 85 genes were found downregulated. Of the up-regulated genes, 224 were induced in both sample sets, however it was obvious that this induction was more pronounced in microglia in &#x003b1;SYN<sup>tg/tg</sup> animals suggesting that with respect to these genes, microglia from &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> animals had a similar but less prominent response to their counterparts with long telomeres. However, 153 genes that were found up-regulated in microglia from &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> animals, were either not induced or even down-regulated in microglia from &#x003b1;SYN<sup>tg/tg</sup> animals, thus for these 153 genes opposing expression patterns were observed suggesting that these genes may point towards differential microglia functions. It is interesting to note here in &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> microglia MMP8, MMP, CXCR2, IL1R1, S100A and S100B were upregulated suggesting that an inflammatory activation of these cells was not completely absent, as indicated by our qPCR analysis from brain stem material.</p><p>To gain more knowledge about how the microglia response was altered between &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> and &#x003b1;SYN<sup>tg/tg</sup> microglia, IPA canonical pathway analysis was performed. It was obvious that LXR/RXR signaling was inhibited in microglia from &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> animals whereas an up-regulation of this pathway was observed in microglia from &#x003b1;SYN<sup>tg/tg</sup> animals. LXR/RXR belong to the family of heterodimeric Type II nuclear receptors [<xref ref-type="bibr" rid="CR74">74</xref>] which in cells of the myeloid lineage drive the acquisition of a cellular state that promotes tissue repair and phagocytosis [<xref ref-type="bibr" rid="CR75">75</xref>]. There are various lines of evidence that LXR/RXR signaling promotes the microglial up-take of amyloid beta, decreases plaque load in mouse models of Alzheimer&#x02019;s disease and improves the memory deficits of these mice [<xref ref-type="bibr" rid="CR76">76</xref>&#x02013;<xref ref-type="bibr" rid="CR78">78</xref>]. As &#x003b1;Syn accumulations are found intraneuronal (see below for discussion) and microglia thus are not in direct contact with these accumulations phagocytosis of &#x003b1;Syn accumulations most likely is not part of the protective program of microglia with long telomeres. Our data linking increased LXR/RXR signaling and prolonged survival of &#x003b1;SYN<sup>tg/tg</sup>animals would suggest a protective function of this signaling pathway also in our Parkinson&#x02019;s disease model. In such scenario wild type microglia would respond to the presence of &#x003b1;Syn accumulating neurons with increased LXR/RXR signaling. Whether this hypothesis holds true and how increased LXR/RXR signaling in microglia finally protects from &#x003b1;Syn pathology remains to be investigated.</p><p>Although much remains to be learned about the different microglia responses and their impact on &#x003b1;Syn pathology and the survival of animals, our data point towards an aging related dysfunction of microglia, which negatively impact neurodegeneration. Microglia in the aged brain have been suggested to be primed for activation, meaning that they acquire a state of exaggerated inflammatory reactivity and/or persistent neuroinflammation. As such microglia priming is considered an important confounding factor in age-associated neurodegenerative diseases [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]. On the other hand, dystrophic microglia, characterized by loss of structural integrity, presence of spheroid inclusions and fragmented cellular processes have been reported in the aged human brain [<xref ref-type="bibr" rid="CR81">81</xref>] or in rodent mouse models of accelerated aging and neurodegeneration [<xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. Since dystrophy in microglia is restricted to aged and neurodegenerative brain tissues, it has been proposed to be the consequence of age-associated telomere shortening and replicative senescence in microglia [<xref ref-type="bibr" rid="CR36">36</xref>]. In contrast to primed microglia, dystrophic microglia have been suggested to be functionally impaired. As a direct consequence the brain becomes more vulnerable potentially leading to neurodegenerative disease [<xref ref-type="bibr" rid="CR84">84</xref>].</p><p>Whether or not telomere shortening in vivo has a direct impact on microglia functionality is currently unclear. We previously demonstrated that telomere shortening did not influence basal microglia gene expression pattern or unchallenged microglia functions [<xref ref-type="bibr" rid="CR73">73</xref>], which is in agreement with the here presented data. However, despite the lack of a morphological response we here also show that microglia with short telomeres displayed a clearly different reaction at the mRNA level in the presence of &#x003b1;Syn pathology. It was surprising to see that microglia with an indistinguishable mRNA expression pattern showed a different response towards pathology and to our knowledge such an observation has not yet been published elsewhere. The reason for this peculiar finding is not clear at the moment, but nevertheless clearly indicating that short telomeres influences microglia gene expression and functionality in response to brain pathology.</p><p>Even though telomere shorting has been described for microglia [<xref ref-type="bibr" rid="CR34">34</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>] we can not exclude effects in other cells. Our data also show that the response of astrocyte is impaired in TERC-/- mice with &#x003b1;Syn pathology. As there is little if any data about telomere shortening in astrocytes [<xref ref-type="bibr" rid="CR34">34</xref>] it is unclear whether this impaired astrocyte response to directly due to the knockout of telomerase in astrocytes. More likely might be that astrocytes responded differently to the changed inflammatory reaction in TERC-/- animals. Moreover, we have recently shown differences in blood brain barrier (BBB) function in third generation TERC-/- animals resulting in increased infiltration of the brain in peripheral inflammation [<xref ref-type="bibr" rid="CR73">73</xref>]. Although in this study BBB function or brain infiltration was not explicitly investigated, we have no data that would be in favor of such disturbance. Please note that we would have seen infiltrated myeloid cells in our microglia isolation experiments that were performed for the mRNA seq analysis.</p><p>Another peculiar finding of this study is that a-syn pathology in 85&#x000a0;week old &#x003b1;SYN<sup>tg/tg</sup> animals was significantly higher than in 75&#x000a0;week old &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> animals. Yet, both lines showed severe motor deficits and premature death raising the question of potential a-syn independent pathological effects in 75&#x000a0;week old &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> animals. Generally it is not entirely clear how [A30P]&#x003b1;SYN pathology leads to motor deficits and death, as neuronal loss is not found in this animal model [<xref ref-type="bibr" rid="CR42">42</xref>]. In preliminary experiments we have compared &#x003b1;Syn accumulations in in 85&#x000a0;week old &#x003b1;SYN<sup>tg/tg</sup> animals and 75&#x000a0;week old &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> animals and did not find striking differences. In both mice the typical &#x003b1;Syn accumulations located most likely in synapses, neuronal cell bodies and neurites, similar to the published observations [<xref ref-type="bibr" rid="CR42">42</xref>] (data not shown). However, a detailed and quantitative comparison of &#x003b1;Syn accumulations in in 85&#x000a0;week old &#x003b1;SYN<sup>tg/tg</sup> animals and 75&#x000a0;week old &#x003b1;SYN<sup>tg/tg</sup>G3Terc<sup>-/-</sup> animals is still pending and would be an important feature of future studies. Moreover, it remains to be established whether potential differences in tau pathology [<xref ref-type="bibr" rid="CR85">85</xref>] may be found in the severe disease in 75&#x000a0;week old &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> animals despite relatively low &#x003b1;Syn pathology.</p></sec><sec id="Sec24"><title>Conclusions</title><p>The data presented here corroborate the assumption that human dystrophic microglia in the aged brain with shorted telomeres are dysfunctional [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR84">84</xref>]. Recent studies indeed have linked telomere dysfunction to various neurological diseases, which indicates the importance of telomere erosion with ageing as a major risk factor in neurodegenerative disorders. As such, telomere length in leukocytes serves as a common predictor for neurological disease and telomere shortening has been observed in patients with dementia and Parkinson&#x02019;s disease [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>]. However, as studies on this subject are controversial [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR89">89</xref>], further research is needed to elucidate the effect of telomere shortening on microglia function and its impact for the development of neurodegenerative diseases.</p></sec></body><back><app-group><app id="App1"><sec id="Sec25"><title>Additional files</title><p><media position="anchor" xlink:href="40478_2016_364_MOESM1_ESM.doc" id="MOESM1"><label>Additional file 1: Table S2.</label><caption><p>Primer sequences which were used for RT-PCR. (DOC 40 kb)</p></caption></media><media position="anchor" xlink:href="40478_2016_364_MOESM2_ESM.pdf" id="MOESM2"><label>Additional file 2: Figure S1.</label><caption><p>Mating scheme for the generation of mouse cohorts. (A) Breeding scheme for generating 3rd generation telomerase knockout and &#x003b1;-synuclein transgenic mice (&#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup>) and corresponding control cohorts. Heterozygous &#x003b1;-synuclein (&#x003b1;SYN) mice were crossed with heterozygous telomerase knockout mice (Terc) to generate double transgenic &#x003b1;SYN<sup>tg/tg</sup> G1Terc<sup>-/-</sup> and single transgenic &#x003b1;SYN<sup>tg/tg</sup>, G1Terc<sup>-/-</sup> and Terc<sup>+/+</sup> mice (G1&#x02009;=&#x02009;first generation of telomerase knockout). These double transgenic &#x003b1;SYN<sup>tg/tg</sup> G1Terc<sup>-/-</sup> mice were crossed with each other to produce &#x003b1;SYN<sup>tg/tg</sup> G2Terc<sup>-/-</sup> mice and finally &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice. (B) Telomere length was measured in neurons of the brainstem using qFISH telomere staining double-stained with Cy5-Neuron N dye. The graph represents telomere length in brainstem in 75&#x000a0;weeks old mice (<italic>n</italic>&#x02009;=&#x02009;5 mice per group). Analyzed were &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> in comparison to &#x003b1;SYN<sup>tg/tg</sup> mice (<italic>P</italic>&#x02009;=&#x02009;0.0012) and G3Terc<sup>-/-</sup> in comparison to Terc<sup>+/+</sup> mice (<italic>P</italic>&#x02009;=&#x02009;0.0079) as well as &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> compared with G3Terc<sup>-/-</sup> (<italic>P</italic>&#x02009;=&#x02009;0.03). (PDF 29 kb)</p></caption></media><media position="anchor" xlink:href="40478_2016_364_MOESM3_ESM.pdf" id="MOESM3"><label>Additional file 3: Figure S2.</label><caption><p>Classification and scoring of phospho-&#x003b1;-synuclein and PK-PET Blot. (A) Classification of phospho-&#x003b1;-synuclein staining into four different scores. Representative pictures for scoring. Score 0: no p-&#x003b1;-synuclein staining, score 1: little staining in brainstem and DpMe, score 2: strong staining in brainstem and DpMe, score 3: strong p-&#x003b1;-synuclein staining in brainstem, DpMe, and cerebellum indicating severe disease progression. (B) Scoring to classify PK-PET Blot. Score 0: no PK resistant aggregates, score 1: light aggregates in brainstem and Deep Mesencepahlic nucleus (DpMe), score 2: clear PK resistant aggregates in brainstem and DpMe, score 3: dominant aggregates in brainstem and DpMe. Score 4: Prominent aggregates in brainstem, DpMe and cerebellum. (PDF 125 kb)</p></caption></media><media position="anchor" xlink:href="40478_2016_364_MOESM4_ESM.pdf" id="MOESM4"><label>Additional file 4: Figure S3.</label><caption><p>Exploratory behavior and string agility. Exploratory behavior of the mice has been analysed using the Open Field System. Several parameters, e.g. the activity, duration and the totally travelled distance were measured in three different zones of the open field: Border, intermediate and center of the open field. 7 to 10 mice of the indicated genotypes were recorded each for 10&#x000a0;min. (A) Activity in the open field and (B) duration of stay in the three indicated zones. &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice did not show a difference in comparison to &#x003b1;SYN<sup>tg/tg</sup> mice and the two control groups. Although a trend can be seen in duration, &#x003b1;SYN<sup>tg/tg</sup> and &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> stay even shorter in the intermediate and the center zone and prefer the border zone in comparison to Terc<sup>+/+</sup> or G3Terc<sup>-/-</sup> mice. (C) String agility test shows no difference between the different groups. (D) Activated astrocytes were measured using GFAP immunohistochemistry. The histogram depicts GFAP positive astrocytes of the brainstem (<italic>n</italic>&#x02009;=&#x02009;4&#x02013;6 mice). &#x003b1;SYN<sup>tg/tg</sup> mice show a significant increase in astrocyte activation (62.35&#x02009;&#x000b1;&#x02009;5.656) in comparison to &#x003b1;SYN<sup>tg/tg</sup> G3Terc<sup>-/-</sup> mice (39&#x02009;&#x000b1;&#x02009;2.383, <italic>P</italic>&#x02009;=&#x02009;0.0159). Furthermore, &#x003b1;SYN<sup>tg/tg</sup> mice with phenotype (85&#x000a0;weeks) show a significant activation (62.35&#x02009;&#x000b1;&#x02009;5.65) if compared with non-phenotypic mice (75&#x000a0;weeks, 33.37&#x02009;&#x000b1;&#x02009;4.086, <italic>P</italic>&#x02009;=&#x02009;0.0095). Terc<sup>+/+</sup> (14.3&#x02009;&#x000b1;&#x02009;7.6) and G3Terc<sup>-/-</sup> mice (10.07&#x02009;&#x000b1;&#x02009;7.10) show low activation levels. (PDF 33 kb)</p></caption></media><media position="anchor" xlink:href="40478_2016_364_MOESM5_ESM.pdf" id="MOESM5"><label>Additional file 5: Figure S4.</label><caption><p>Schematic representation of the parameter analyzed in 3D-reconstructed microglia. Automated analysis of each structural characteristic was performed using Imaris Bitplane software. (PDF 50 kb)</p></caption></media></p></sec></app></app-group><ack><title>Acknowledgements</title><p>The study was funded by grants from the German Research Council (DFG) (BI 668/2-2 and BI 668/5-1) to K.B., German Ministry for Research and Education (DMBF) grant e:bio &#x02013; Modul I &#x02013;ReelinSys (Project B: 031 6174A) to K.B.</p><sec id="FPar1"><title>Authors&#x02019; contributions</title><p>AS performed experiments, analyzed and interpreted data and wrote the paper, SD, NB, SK, BJ performed experiments and analyzed data, IH, BE and EB conducted all bioinformatics analyses and wrote the paper, PK, BH, AL, SS interpreted data, edited the paper, BE, KLR and KB designed research, interpreted data and wrote the paper, KB, KLR and EB conceived the study, designed research, interpreted data and wrote the paper. All authors read and approved the final manuscript.</p></sec><sec id="FPar2"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lau</surname><given-names>LM</given-names></name><name><surname>Breteler</surname><given-names>MM</given-names></name></person-group><article-title>Epidemiology of Parkinson&#x02019;s disease</article-title><source>Lancet Neurol</source><year>2006</year><volume>5</volume><fpage>525</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(06)70471-9</pub-id><?supplied-pmid 16713924?><pub-id pub-id-type="pmid">16713924</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Tan</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>JT</given-names></name></person-group><article-title>Link between the SNCA gene and parkinsonism</article-title><source>Neurobiol Aging</source><year>2015</year><volume>36</volume><fpage>1505</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2014.10.042</pub-id><?supplied-pmid 25554495?><pub-id pub-id-type="pmid">25554495</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goedert</surname><given-names>M</given-names></name><name><surname>Spillantini</surname><given-names>MG</given-names></name><name><surname>Serpell</surname><given-names>LC</given-names></name><name><surname>Berriman</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>MJ</given-names></name><name><surname>Jakes</surname><given-names>R</given-names></name><etal/></person-group><article-title>From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases</article-title><source>Philos Trans R Soc Lond B Biol Sci</source><year>2001</year><volume>356</volume><fpage>213</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1098/rstb.2000.0767</pub-id><?supplied-pmid 11260802?><pub-id pub-id-type="pmid">11260802</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baba</surname><given-names>M</given-names></name><name><surname>Nakajo</surname><given-names>S</given-names></name><name><surname>Tu</surname><given-names>PH</given-names></name><name><surname>Tomita</surname><given-names>T</given-names></name><name><surname>Nakaya</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><etal/></person-group><article-title>Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson&#x02019;s disease and dementia with Lewy bodies</article-title><source>Am J Pathol</source><year>1998</year><volume>152</volume><fpage>879</fpage><lpage>84</lpage><?supplied-pmid 9546347?><pub-id pub-id-type="pmid">9546347</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winner</surname><given-names>B</given-names></name><name><surname>Jappelli</surname><given-names>R</given-names></name><name><surname>Maji</surname><given-names>SK</given-names></name><name><surname>Desplats</surname><given-names>PA</given-names></name><name><surname>Boyer</surname><given-names>L</given-names></name><name><surname>Aigner</surname><given-names>S</given-names></name><etal/></person-group><article-title>In vivo demonstration that alpha-synuclein oligomers are toxic</article-title><source>Proc Natl Acad Sci U S A</source><year>2011</year><volume>108</volume><fpage>4194</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1073/pnas.1100976108</pub-id><pub-id pub-id-type="pmid">21325059</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uversky</surname><given-names>VN</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Fink</surname><given-names>AL</given-names></name></person-group><article-title>Evidence for a partially folded intermediate in alpha-synuclein fibril formation</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>10737</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1074/jbc.M010907200</pub-id><?supplied-pmid 11152691?><pub-id pub-id-type="pmid">11152691</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Agnaf</surname><given-names>OM</given-names></name><name><surname>Salem</surname><given-names>SA</given-names></name><name><surname>Paleologou</surname><given-names>KE</given-names></name><name><surname>Curran</surname><given-names>MD</given-names></name><name><surname>Gibson</surname><given-names>MJ</given-names></name><name><surname>Court</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson&#x02019;s disease</article-title><source>FASEB J</source><year>2006</year><volume>20</volume><fpage>419</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1096/fj.03-1449com</pub-id><?supplied-pmid 16507759?><pub-id pub-id-type="pmid">16507759</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danzer</surname><given-names>KM</given-names></name><name><surname>Haasen</surname><given-names>D</given-names></name><name><surname>Karow</surname><given-names>AR</given-names></name><name><surname>Moussaud</surname><given-names>S</given-names></name><name><surname>Habeck</surname><given-names>M</given-names></name><name><surname>Giese</surname><given-names>A</given-names></name><etal/></person-group><article-title>Different species of alpha-synuclein oligomers induce calcium influx and seeding</article-title><source>J Neurosci</source><year>2007</year><volume>27</volume><fpage>9220</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2617-07.2007</pub-id><?supplied-pmid 17715357?><pub-id pub-id-type="pmid">17715357</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biber</surname><given-names>K</given-names></name><name><surname>Moller</surname><given-names>T</given-names></name><name><surname>Boddeke</surname><given-names>E</given-names></name><name><surname>Prinz</surname><given-names>M</given-names></name></person-group><article-title>Central nervous system myeloid cells as drug targets: current status and translational challenges</article-title><source>Nat Rev Drug Discov</source><year>2016</year><volume>15</volume><fpage>110</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1038/nrd.2015.14</pub-id><?supplied-pmid 26634996?><pub-id pub-id-type="pmid">26634996</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kierdorf</surname><given-names>K</given-names></name><name><surname>Erny</surname><given-names>D</given-names></name><name><surname>Goldmann</surname><given-names>T</given-names></name><name><surname>Sander</surname><given-names>V</given-names></name><name><surname>Schulz</surname><given-names>C</given-names></name><name><surname>Perdiguero</surname><given-names>EG</given-names></name><etal/></person-group><article-title>Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways</article-title><source>Nat Neurosci</source><year>2013</year><volume>16</volume><fpage>273</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1038/nn.3318</pub-id><?supplied-pmid 23334579?><pub-id pub-id-type="pmid">23334579</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginhoux</surname><given-names>F</given-names></name><name><surname>Greter</surname><given-names>M</given-names></name><name><surname>Leboeuf</surname><given-names>M</given-names></name><name><surname>Nandi</surname><given-names>S</given-names></name><name><surname>See</surname><given-names>P</given-names></name><name><surname>Gokhan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Fate mapping analysis reveals that adult microglia derive from primitive macrophages</article-title><source>Science</source><year>2010</year><volume>330</volume><fpage>841</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1126/science.1194637</pub-id><?supplied-pmid 20966214?><pub-id pub-id-type="pmid">20966214</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>C</given-names></name><name><surname>Gomez Perdiguero</surname><given-names>E</given-names></name><name><surname>Chorro</surname><given-names>L</given-names></name><name><surname>Szabo-Rogers</surname><given-names>H</given-names></name><name><surname>Cagnard</surname><given-names>N</given-names></name><name><surname>Kierdorf</surname><given-names>K</given-names></name><etal/></person-group><article-title>A lineage of myeloid cells independent of Myb and hematopoietic stem cells</article-title><source>Science</source><year>2012</year><volume>336</volume><fpage>86</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1126/science.1219179</pub-id><?supplied-pmid 22442384?><pub-id pub-id-type="pmid">22442384</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tremblay</surname><given-names>ME</given-names></name><name><surname>Lowery</surname><given-names>RL</given-names></name><name><surname>Majewska</surname><given-names>AK</given-names></name></person-group><article-title>Microglial interactions with synapses are modulated by visual experience</article-title><source>PLoS Biol</source><year>2010</year><volume>8</volume><fpage>e1000527</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.1000527</pub-id><?supplied-pmid 21072242?><pub-id pub-id-type="pmid">21072242</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sierra</surname><given-names>A</given-names></name><name><surname>Navascues</surname><given-names>J</given-names></name><name><surname>Cuadros</surname><given-names>MA</given-names></name><name><surname>Calvente</surname><given-names>R</given-names></name><name><surname>Martin-Oliva</surname><given-names>D</given-names></name><name><surname>Ferrer-Martin</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Expression of inducible nitric oxide synthase (iNOS) in microglia of the developing quail retina</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e106048</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0106048</pub-id><?supplied-pmid 25170849?><pub-id pub-id-type="pmid">25170849</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tremblay</surname><given-names>ME</given-names></name><name><surname>Lowery</surname><given-names>RL</given-names></name><name><surname>Majewska</surname><given-names>AK</given-names></name></person-group><article-title>Microglial interactions with synapses are modulated by visual experience</article-title><source>PLoS Biol</source><year>2011</year><volume>8</volume><fpage>e1000527</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.1000527</pub-id><pub-id pub-id-type="pmid">21072242</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biber</surname><given-names>K</given-names></name><name><surname>Owens</surname><given-names>T</given-names></name><name><surname>Boddeke</surname><given-names>E</given-names></name></person-group><article-title>What is microglia neurotoxicity (Not)?</article-title><source>Glia</source><year>2014</year><volume>62</volume><fpage>841</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1002/glia.22654</pub-id><?supplied-pmid 24590682?><pub-id pub-id-type="pmid">24590682</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butovsky</surname><given-names>O</given-names></name><name><surname>Jedrychowski</surname><given-names>MP</given-names></name><name><surname>Cialic</surname><given-names>R</given-names></name><name><surname>Krasemann</surname><given-names>S</given-names></name><name><surname>Murugaiyan</surname><given-names>G</given-names></name><name><surname>Fanek</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice</article-title><source>Ann Neurol</source><year>2015</year><volume>77</volume><fpage>75</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1002/ana.24304</pub-id><?supplied-pmid 25381879?><pub-id pub-id-type="pmid">25381879</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanisch</surname><given-names>UK</given-names></name></person-group><article-title>Functional diversity of microglia - how heterogeneous are they to begin with?</article-title><source>Front Cell Neurosci</source><year>2013</year><volume>7</volume><fpage>65</fpage><pub-id pub-id-type="doi">10.3389/fncel.2013.00065</pub-id><?supplied-pmid 23717262?><pub-id pub-id-type="pmid">23717262</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hellwig</surname><given-names>S</given-names></name><name><surname>Heinrich</surname><given-names>A</given-names></name><name><surname>Biber</surname><given-names>K</given-names></name></person-group><article-title>The brain&#x02019;s best friend: microglial neurotoxicity revisited</article-title><source>Front Cell Neurosci</source><year>2013</year><volume>7</volume><fpage>71</fpage><pub-id pub-id-type="doi">10.3389/fncel.2013.00071</pub-id><?supplied-pmid 23734099?><pub-id pub-id-type="pmid">23734099</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kettenmann</surname><given-names>H</given-names></name><name><surname>Kirchhoff</surname><given-names>F</given-names></name><name><surname>Verkhratsky</surname><given-names>A</given-names></name></person-group><article-title>Microglia: new roles for the synaptic stripper</article-title><source>Neuron</source><year>2013</year><volume>77</volume><fpage>10</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2012.12.023</pub-id><?supplied-pmid 23312512?><pub-id pub-id-type="pmid">23312512</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>London</surname><given-names>A</given-names></name><name><surname>Cohen</surname><given-names>M</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name></person-group><article-title>Microglia and monocyte-derived macrophages: functionally distinct populations that act in concert in CNS plasticity and repair</article-title><source>Front Cell Neurosci</source><year>2013</year><volume>7</volume><fpage>34</fpage><pub-id pub-id-type="doi">10.3389/fncel.2013.00034</pub-id><?supplied-pmid 23596391?><pub-id pub-id-type="pmid">23596391</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sierra</surname><given-names>A</given-names></name><name><surname>Beccari</surname><given-names>S</given-names></name><name><surname>Diaz-Aparicio</surname><given-names>I</given-names></name><name><surname>Encinas</surname><given-names>JM</given-names></name><name><surname>Comeau</surname><given-names>S</given-names></name><name><surname>Tremblay</surname><given-names>ME</given-names></name></person-group><article-title>Surveillance, phagocytosis, and inflammation: how never-resting microglia influence adult hippocampal neurogenesis</article-title><source>Neural Plast</source><year>2013</year><volume>2014</volume><fpage>610343</fpage><pub-id pub-id-type="pmid">24772353</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vinet</surname><given-names>J</given-names></name><name><surname>Weering</surname><given-names>HR</given-names></name><name><surname>Heinrich</surname><given-names>A</given-names></name><name><surname>Kalin</surname><given-names>RE</given-names></name><name><surname>Wegner</surname><given-names>A</given-names></name><name><surname>Brouwer</surname><given-names>N</given-names></name><etal/></person-group><article-title>Neuroprotective function for ramified microglia in hippocampal excitotoxicity</article-title><source>J Neuroinflammation</source><year>2012</year><volume>9</volume><fpage>27</fpage><pub-id pub-id-type="doi">10.1186/1742-2094-9-27</pub-id><?supplied-pmid 22293457?><pub-id pub-id-type="pmid">22293457</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Br&#x000fc;ck DW, GK. Stefanova, N. Fellner, L. Glia and alpha-synuclein in neurodegeneration: A complex interaction. Neurobiol Dis. 2016;85:262&#x02013;74.</mixed-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>J</given-names></name><name><surname>Mastroeni</surname><given-names>D</given-names></name><name><surname>Leonard</surname><given-names>B</given-names></name><name><surname>Joyce</surname><given-names>J</given-names></name><name><surname>Grover</surname><given-names>A</given-names></name></person-group><article-title>Neuroinflammation in Alzheimer&#x02019;s disease and Parkinson&#x02019;s disease: are microglia pathogenic in either disorder?</article-title><source>Int Rev Neurobiol</source><year>2007</year><volume>82</volume><fpage>235</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/S0074-7742(07)82012-5</pub-id><?supplied-pmid 17678964?><pub-id pub-id-type="pmid">17678964</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Power</surname><given-names>JH</given-names></name><name><surname>Blumbergs</surname><given-names>PC</given-names></name></person-group><article-title>Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson&#x02019;s disease and dementia with Lewy bodies</article-title><source>Acta Neuropathol</source><year>2009</year><volume>117</volume><fpage>63</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1007/s00401-008-0438-3</pub-id><?supplied-pmid 18853169?><pub-id pub-id-type="pmid">18853169</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calne</surname><given-names>DB</given-names></name><name><surname>Eisen</surname><given-names>A</given-names></name><name><surname>McGeer</surname><given-names>E</given-names></name><name><surname>Spencer</surname><given-names>P</given-names></name></person-group><article-title>Alzheimer&#x02019;s disease, Parkinson&#x02019;s disease, and motoneurone disease: abiotrophic interaction between ageing and environment?</article-title><source>Lancet</source><year>1986</year><volume>2</volume><fpage>1067</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(86)90469-1</pub-id><?supplied-pmid 2877227?><pub-id pub-id-type="pmid">2877227</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fearnley</surname><given-names>JM</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name></person-group><article-title>Ageing and Parkinson&#x02019;s disease: substantia nigra regional selectivity</article-title><source>Brain</source><year>1991</year><volume>114</volume><issue>Pt 5</issue><fpage>2283</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1093/brain/114.5.2283</pub-id><?supplied-pmid 1933245?><pub-id pub-id-type="pmid">1933245</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hornykiewicz</surname><given-names>O</given-names></name></person-group><article-title>Ageing and neurotoxins as causative factors in idiopathic Parkinson&#x02019;s disease--a critical analysis of the neurochemical evidence</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry</source><year>1989</year><volume>13</volume><fpage>319</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/0278-5846(89)90121-8</pub-id><?supplied-pmid 2664888?><pub-id pub-id-type="pmid">2664888</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>VH</given-names></name></person-group><article-title>Stress primes microglia to the presence of systemic inflammation: implications for environmental influences on the brain</article-title><source>Brain Behav Immun</source><year>2007</year><volume>21</volume><fpage>45</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2006.08.004</pub-id><?supplied-pmid 17011745?><pub-id pub-id-type="pmid">17011745</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackburn</surname><given-names>EH</given-names></name></person-group><article-title>Telomere states and cell fates</article-title><source>Nature</source><year>2000</year><volume>408</volume><fpage>53</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/35040500</pub-id><?supplied-pmid 11081503?><pub-id pub-id-type="pmid">11081503</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damjanovic</surname><given-names>AK</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Glaser</surname><given-names>R</given-names></name><name><surname>Kiecolt-Glaser</surname><given-names>JK</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Laskowski</surname><given-names>B</given-names></name><etal/></person-group><article-title>Accelerated telomere erosion is associated with a declining immune function of caregivers of Alzheimer&#x02019;s disease patients</article-title><source>J Immunol</source><year>2007</year><volume>179</volume><fpage>4249</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.179.6.4249</pub-id><?supplied-pmid 17785865?><pub-id pub-id-type="pmid">17785865</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lechel</surname><given-names>A</given-names></name><name><surname>Holstege</surname><given-names>H</given-names></name><name><surname>Begus</surname><given-names>Y</given-names></name><name><surname>Schienke</surname><given-names>A</given-names></name><name><surname>Kamino</surname><given-names>K</given-names></name><name><surname>Lehmann</surname><given-names>U</given-names></name><etal/></person-group><article-title>Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease</article-title><source>Gastroenterology</source><year>2007</year><volume>132</volume><fpage>1465</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2007.01.045</pub-id><?supplied-pmid 17433324?><pub-id pub-id-type="pmid">17433324</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flanary</surname><given-names>BE</given-names></name><name><surname>Streit</surname><given-names>WJ</given-names></name></person-group><article-title>Progressive telomere shortening occurs in cultured rat microglia, but not astrocytes</article-title><source>Glia</source><year>2004</year><volume>45</volume><fpage>75</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1002/glia.10301</pub-id><?supplied-pmid 14648548?><pub-id pub-id-type="pmid">14648548</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flanary</surname><given-names>BE</given-names></name><name><surname>Streit</surname><given-names>WJ</given-names></name></person-group><article-title>Telomeres shorten with age in rat cerebellum and cortex in vivo</article-title><source>J Anti Aging Med</source><year>2003</year><volume>6</volume><fpage>299</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1089/109454503323028894</pub-id><?supplied-pmid 15142431?><pub-id pub-id-type="pmid">15142431</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flanary</surname><given-names>BE</given-names></name><name><surname>Sammons</surname><given-names>NW</given-names></name><name><surname>Nguyen</surname><given-names>C</given-names></name><name><surname>Walker</surname><given-names>D</given-names></name><name><surname>Streit</surname><given-names>WJ</given-names></name></person-group><article-title>Evidence that aging and amyloid promote microglial cell senescence</article-title><source>Rejuvenation Res</source><year>2007</year><volume>10</volume><fpage>61</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1089/rej.2006.9096</pub-id><?supplied-pmid 17378753?><pub-id pub-id-type="pmid">17378753</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>JZ</given-names></name><name><surname>Maeda</surname><given-names>T</given-names></name><name><surname>Sugano</surname><given-names>M</given-names></name><name><surname>Oyama</surname><given-names>J</given-names></name><name><surname>Higuchi</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><etal/></person-group><article-title>A percentage analysis of the telomere length in Parkinson&#x02019;s disease patients</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>2008</year><volume>63</volume><fpage>467</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1093/gerona/63.5.467</pub-id><?supplied-pmid 18511749?><pub-id pub-id-type="pmid">18511749</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watfa</surname><given-names>G</given-names></name><name><surname>Dragonas</surname><given-names>C</given-names></name><name><surname>Brosche</surname><given-names>T</given-names></name><name><surname>Dittrich</surname><given-names>R</given-names></name><name><surname>Sieber</surname><given-names>CC</given-names></name><name><surname>Alecu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Study of telomere length and different markers of oxidative stress in patients with Parkinson&#x02019;s disease</article-title><source>J Nutr Health Aging</source><year>2009</year><volume>15</volume><fpage>277</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1007/s12603-010-0275-7</pub-id><pub-id pub-id-type="pmid">21437559</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>McGrath</surname><given-names>M</given-names></name><name><surname>Deer</surname><given-names>D</given-names></name><name><surname>De Vivo</surname><given-names>I</given-names></name><etal/></person-group><article-title>Telomere length and risk of Parkinson&#x02019;s disease</article-title><source>Mov Disord</source><year>2008</year><volume>23</volume><fpage>302</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1002/mds.21867</pub-id><?supplied-pmid 18044760?><pub-id pub-id-type="pmid">18044760</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>T</given-names></name><name><surname>Guan</surname><given-names>JZ</given-names></name><name><surname>Koyanagi</surname><given-names>M</given-names></name><name><surname>Higuchi</surname><given-names>Y</given-names></name><name><surname>Makino</surname><given-names>N</given-names></name></person-group><article-title>Aging-associated alteration of telomere length and subtelomeric status in female patients with Parkinson&#x02019;s disease</article-title><source>J Neurogenet</source><year>2012</year><volume>26</volume><fpage>245</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.3109/01677063.2011.651665</pub-id><?supplied-pmid 22364520?><pub-id pub-id-type="pmid">22364520</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahle</surname><given-names>PJ</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Ozmen</surname><given-names>L</given-names></name><name><surname>Muller</surname><given-names>V</given-names></name><name><surname>Odoy</surname><given-names>S</given-names></name><name><surname>Okamoto</surname><given-names>N</given-names></name><etal/></person-group><article-title>Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model</article-title><source>Am J Pathol</source><year>2001</year><volume>159</volume><fpage>2215</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)63072-6</pub-id><?supplied-pmid 11733371?><pub-id pub-id-type="pmid">11733371</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahle</surname><given-names>PJ</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Ozmen</surname><given-names>L</given-names></name><name><surname>Muller</surname><given-names>V</given-names></name><name><surname>Jacobsen</surname><given-names>H</given-names></name><name><surname>Schindzielorz</surname><given-names>A</given-names></name><etal/></person-group><article-title>Subcellular localization of wild-type and Parkinson&#x02019;s disease-associated mutant alpha -synuclein in human and transgenic mouse brain</article-title><source>J Neurosci</source><year>2000</year><volume>20</volume><fpage>6365</fpage><lpage>73</lpage><?supplied-pmid 10964942?><pub-id pub-id-type="pmid">10964942</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Kahle</surname><given-names>PJ</given-names></name><name><surname>Giasson</surname><given-names>BI</given-names></name><name><surname>Ozmen</surname><given-names>L</given-names></name><name><surname>Borroni</surname><given-names>E</given-names></name><name><surname>Spooren</surname><given-names>W</given-names></name><etal/></person-group><article-title>Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies</article-title><source>J Clin Invest</source><year>2002</year><volume>110</volume><fpage>1429</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1172/JCI200215777</pub-id><?supplied-pmid 12438441?><pub-id pub-id-type="pmid">12438441</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blasco</surname><given-names>MA</given-names></name><name><surname>Lee</surname><given-names>HW</given-names></name><name><surname>Hande</surname><given-names>MP</given-names></name><name><surname>Samper</surname><given-names>E</given-names></name><name><surname>Lansdorp</surname><given-names>PM</given-names></name><name><surname>DePinho</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Telomere shortening and tumor formation by mouse cells lacking telomerase RNA</article-title><source>Cell</source><year>1997</year><volume>91</volume><fpage>25</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(01)80006-4</pub-id><?supplied-pmid 9335332?><pub-id pub-id-type="pmid">9335332</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="other">Carter RJ, Morton J, Dunnett SB. Motor coordination and balance in rodents. Curr Protoc Neurosci. 2001;Chapter 8:Unit 8 12.</mixed-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bevins</surname><given-names>RA</given-names></name><name><surname>Besheer</surname><given-names>J</given-names></name></person-group><article-title>Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study &#x02018;recognition memory&#x02019;</article-title><source>Nat Protoc</source><year>2006</year><volume>1</volume><fpage>1306</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.205</pub-id><?supplied-pmid 17406415?><pub-id pub-id-type="pmid">17406415</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freichel</surname><given-names>C</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Ballard</surname><given-names>T</given-names></name><name><surname>Muller</surname><given-names>V</given-names></name><name><surname>Woolley</surname><given-names>M</given-names></name><name><surname>Ozmen</surname><given-names>L</given-names></name><etal/></person-group><article-title>Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice</article-title><source>Neurobiol Aging</source><year>2007</year><volume>28</volume><fpage>1421</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2006.06.013</pub-id><?supplied-pmid 16872721?><pub-id pub-id-type="pmid">16872721</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satyanarayana</surname><given-names>A</given-names></name><name><surname>Wiemann</surname><given-names>SU</given-names></name><name><surname>Buer</surname><given-names>J</given-names></name><name><surname>Lauber</surname><given-names>J</given-names></name><name><surname>Dittmar</surname><given-names>KE</given-names></name><name><surname>Wustefeld</surname><given-names>T</given-names></name><etal/></person-group><article-title>Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells</article-title><source>EMBO J</source><year>2003</year><volume>22</volume><fpage>4003</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1093/emboj/cdg367</pub-id><?supplied-pmid 12881434?><pub-id pub-id-type="pmid">12881434</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other">Poon SS, Lansdorp PM. Quantitative fluorescence in situ hybridization (Q-FISH). Curr Protoc Cell Biol. 2001;Chapter 18:Unit 18 4.</mixed-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vainchtein</surname><given-names>ID</given-names></name><name><surname>Vinet</surname><given-names>J</given-names></name><name><surname>Brouwer</surname><given-names>N</given-names></name><name><surname>Brendecke</surname><given-names>S</given-names></name><name><surname>Biagini</surname><given-names>G</given-names></name><name><surname>Biber</surname><given-names>K</given-names></name><etal/></person-group><article-title>In acute experimental autoimmune encephalomyelitis, infiltrating macrophages are immune activated, whereas microglia remain immune suppressed</article-title><source>Glia</source><year>2014</year><volume>62</volume><fpage>1724</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1002/glia.22711</pub-id><?supplied-pmid 24953459?><pub-id pub-id-type="pmid">24953459</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><etal/></person-group><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><year>2013</year><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><?supplied-pmid 23104886?><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roussos</surname><given-names>P</given-names></name><name><surname>Katsel</surname><given-names>P</given-names></name><name><surname>Davis</surname><given-names>KL</given-names></name><name><surname>Siever</surname><given-names>LJ</given-names></name><name><surname>Haroutunian</surname><given-names>V</given-names></name></person-group><article-title>A system-level transcriptomic analysis of schizophrenia using postmortem brain tissue samples</article-title><source>Arch Gen Psychiatry</source><year>2012</year><volume>69</volume><fpage>1205</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2012.704</pub-id><?supplied-pmid 22868662?><pub-id pub-id-type="pmid">22868662</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anders</surname><given-names>S</given-names></name><name><surname>Pyl</surname><given-names>PT</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><article-title>HTSeq--a Python framework to work with high-throughput sequencing data</article-title><source>Bioinformatics</source><year>2014</year><volume>31</volume><fpage>166</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu638</pub-id><?supplied-pmid 25260700?><pub-id pub-id-type="pmid">25260700</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>MD</given-names></name><name><surname>McCarthy</surname><given-names>DJ</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><article-title>edgeR: a Bioconductor package for differential expression analysis of digital gene expression data</article-title><source>Bioinformatics</source><year>2010</year><volume>26</volume><fpage>139</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp616</pub-id><?supplied-pmid 19910308?><pub-id pub-id-type="pmid">19910308</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Huang</surname><given-names>W</given-names></name><name><surname>Sherman</surname><given-names>BT</given-names></name><name><surname>Lempicki</surname><given-names>RA</given-names></name></person-group><article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title><source>Nat Protoc</source><year>2009</year><volume>4</volume><fpage>44</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1038/nprot.2008.211</pub-id><pub-id pub-id-type="pmid">19131956</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spinelli</surname><given-names>KJ</given-names></name><name><surname>Taylor</surname><given-names>JK</given-names></name><name><surname>Osterberg</surname><given-names>VR</given-names></name><name><surname>Churchill</surname><given-names>MJ</given-names></name><name><surname>Pollock</surname><given-names>E</given-names></name><name><surname>Moore</surname><given-names>C</given-names></name><etal/></person-group><article-title>Presynaptic alpha-synuclein aggregation in a mouse model of Parkinson&#x02019;s disease</article-title><source>J Neurosci</source><year>2014</year><volume>34</volume><fpage>2037</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2581-13.2014</pub-id><?supplied-pmid 24501346?><pub-id pub-id-type="pmid">24501346</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Arawaka</surname><given-names>S</given-names></name></person-group><article-title>The role of Ser129 phosphorylation of alpha-synuclein in neurodegeneration of Parkinson&#x02019;s disease: a review of in vivo models</article-title><source>Rev Neurosci</source><year>2013</year><volume>24</volume><fpage>115</fpage><lpage>23</lpage><?supplied-pmid 23314528?><pub-id pub-id-type="pmid">23314528</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="other">Fleming SM, Ekhator OR, Ghisays V. Assessment of sensorimotor function in mouse models of Parkinson&#x02019;s disease. J Vis Exp. 2013. doi:10.3791/50303.</mixed-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plaas</surname><given-names>M</given-names></name><name><surname>Karis</surname><given-names>A</given-names></name><name><surname>Innos</surname><given-names>J</given-names></name><name><surname>Rebane</surname><given-names>E</given-names></name><name><surname>Baekelandt</surname><given-names>V</given-names></name><name><surname>Vaarmann</surname><given-names>A</given-names></name><etal/></person-group><article-title>Alpha-synuclein A30P point-mutation generates age-dependent nigrostriatal deficiency in mice</article-title><source>J Physiol Pharmacol</source><year>2008</year><volume>59</volume><fpage>205</fpage><lpage>16</lpage><?supplied-pmid 18622040?><pub-id pub-id-type="pmid">18622040</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hebert</surname><given-names>G</given-names></name><name><surname>Arsaut</surname><given-names>J</given-names></name><name><surname>Dantzer</surname><given-names>R</given-names></name><name><surname>Demotes-Mainard</surname><given-names>J</given-names></name></person-group><article-title>Time-course of the expression of inflammatory cytokines and matrix metalloproteinases in the striatum and mesencephalon of mice injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a dopaminergic neurotoxin</article-title><source>Neurosci Lett</source><year>2003</year><volume>349</volume><fpage>191</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/S0304-3940(03)00832-2</pub-id><pub-id pub-id-type="pmid">12951201</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurkowska-Jastrzebska</surname><given-names>I</given-names></name><name><surname>Wronska</surname><given-names>A</given-names></name><name><surname>Kohutnicka</surname><given-names>M</given-names></name><name><surname>Czlonkowski</surname><given-names>A</given-names></name><name><surname>Czlonkowska</surname><given-names>A</given-names></name></person-group><article-title>The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse</article-title><source>Exp Neurol</source><year>1999</year><volume>156</volume><fpage>50</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1006/exnr.1998.6993</pub-id><?supplied-pmid 10192776?><pub-id pub-id-type="pmid">10192776</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerhard</surname><given-names>A</given-names></name><name><surname>Pavese</surname><given-names>N</given-names></name><name><surname>Hotton</surname><given-names>G</given-names></name><name><surname>Turkheimer</surname><given-names>F</given-names></name><name><surname>Es</surname><given-names>M</given-names></name><name><surname>Hammers</surname><given-names>A</given-names></name><etal/></person-group><article-title>In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson&#x02019;s disease</article-title><source>Neurobiol Dis</source><year>2006</year><volume>21</volume><fpage>404</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2005.08.002</pub-id><?supplied-pmid 16182554?><pub-id pub-id-type="pmid">16182554</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGeer</surname><given-names>PL</given-names></name><name><surname>Itagaki</surname><given-names>S</given-names></name><name><surname>Boyes</surname><given-names>BE</given-names></name><name><surname>McGeer</surname><given-names>EG</given-names></name></person-group><article-title>Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson&#x02019;s and Alzheimer&#x02019;s disease brains</article-title><source>Neurology</source><year>1988</year><volume>38</volume><fpage>1285</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1212/WNL.38.8.1285</pub-id><?supplied-pmid 3399080?><pub-id pub-id-type="pmid">3399080</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orr</surname><given-names>CF</given-names></name><name><surname>Rowe</surname><given-names>DB</given-names></name><name><surname>Mizuno</surname><given-names>Y</given-names></name><name><surname>Mori</surname><given-names>H</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name></person-group><article-title>A possible role for humoral immunity in the pathogenesis of Parkinson&#x02019;s disease</article-title><source>Brain</source><year>2005</year><volume>128</volume><fpage>2665</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1093/brain/awh625</pub-id><?supplied-pmid 16219675?><pub-id pub-id-type="pmid">16219675</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Codolo</surname><given-names>G</given-names></name><name><surname>Plotegher</surname><given-names>N</given-names></name><name><surname>Pozzobon</surname><given-names>T</given-names></name><name><surname>Brucale</surname><given-names>M</given-names></name><name><surname>Tessari</surname><given-names>I</given-names></name><name><surname>Bubacco</surname><given-names>L</given-names></name><etal/></person-group><article-title>Triggering of inflammasome by aggregated alpha-synuclein, an inflammatory response in synucleinopathies</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e55375</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0055375</pub-id><?supplied-pmid 23383169?><pub-id pub-id-type="pmid">23383169</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daniele</surname><given-names>SG</given-names></name><name><surname>Beraud</surname><given-names>D</given-names></name><name><surname>Davenport</surname><given-names>C</given-names></name><name><surname>Cheng</surname><given-names>K</given-names></name><name><surname>Yin</surname><given-names>H</given-names></name><name><surname>Maguire-Zeiss</surname><given-names>KA</given-names></name></person-group><article-title>Activation of MyD88-dependent TLR1/2 signaling by misfolded alpha-synuclein, a protein linked to neurodegenerative disorders</article-title><source>Sci Signal</source><year>2013</year><volume>8</volume><fpage>ra45</fpage><pub-id pub-id-type="doi">10.1126/scisignal.2005965</pub-id><pub-id pub-id-type="pmid">25969543</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Pei</surname><given-names>Z</given-names></name><name><surname>Miller</surname><given-names>DS</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Block</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson&#x02019;s disease</article-title><source>FASEB J</source><year>2005</year><volume>19</volume><fpage>533</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1096/fj.04-2751com</pub-id><?supplied-pmid 15791003?><pub-id pub-id-type="pmid">15791003</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Paik</surname><given-names>SR</given-names></name><name><surname>Jou</surname><given-names>I</given-names></name><name><surname>Park</surname><given-names>SM</given-names></name></person-group><article-title>Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinson&#x02019;s disease</article-title><source>Glia</source><year>2008</year><volume>56</volume><fpage>1215</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1002/glia.20691</pub-id><?supplied-pmid 18449945?><pub-id pub-id-type="pmid">18449945</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Block</surname><given-names>ML</given-names></name><name><surname>Hong</surname><given-names>JS</given-names></name></person-group><article-title>Chronic microglial activation and progressive dopaminergic neurotoxicity</article-title><source>Biochem Soc Trans</source><year>2007</year><volume>35</volume><fpage>1127</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1042/BST0351127</pub-id><?supplied-pmid 17956294?><pub-id pub-id-type="pmid">17956294</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouchi</surname><given-names>Y</given-names></name><name><surname>Yoshikawa</surname><given-names>E</given-names></name><name><surname>Sekine</surname><given-names>Y</given-names></name><name><surname>Futatsubashi</surname><given-names>M</given-names></name><name><surname>Kanno</surname><given-names>T</given-names></name><name><surname>Ogusu</surname><given-names>T</given-names></name><etal/></person-group><article-title>Microglial activation and dopamine terminal loss in early Parkinson&#x02019;s disease</article-title><source>Ann Neurol</source><year>2005</year><volume>57</volume><fpage>168</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1002/ana.20338</pub-id><?supplied-pmid 15668962?><pub-id pub-id-type="pmid">15668962</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Suk</surname><given-names>JE</given-names></name><name><surname>Bae</surname><given-names>EJ</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Paik</surname><given-names>SR</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name></person-group><article-title>Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein</article-title><source>Int J Biochem Cell Biol</source><year>2008</year><volume>40</volume><fpage>1835</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2008.01.017</pub-id><?supplied-pmid 18291704?><pub-id pub-id-type="pmid">18291704</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefanova</surname><given-names>N</given-names></name><name><surname>Fellner</surname><given-names>L</given-names></name><name><surname>Reindl</surname><given-names>M</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name><name><surname>Wenning</surname><given-names>GK</given-names></name></person-group><article-title>Toll-like receptor 4 promotes alpha-synuclein clearance and survival of nigral dopaminergic neurons</article-title><source>Am J Pathol</source><year>2011</year><volume>179</volume><fpage>954</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2011.04.013</pub-id><?supplied-pmid 21801874?><pub-id pub-id-type="pmid">21801874</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>DD</given-names></name><name><surname>Moser</surname><given-names>J</given-names></name><name><surname>van der Pol</surname><given-names>SM</given-names></name><name><surname>van Os</surname><given-names>RP</given-names></name><name><surname>Holtman</surname><given-names>IR</given-names></name><name><surname>Brouwer</surname><given-names>N</given-names></name><etal/></person-group><article-title>Enhanced microglial pro-inflammatory response to lipopolysaccharide correlates with brain infiltration and blood-brain barrier dysregulation in a mouse model of telomere shortening</article-title><source>Aging Cell</source><year>2015</year><volume>14</volume><fpage>1003</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1111/acel.12370</pub-id><?supplied-pmid 26238505?><pub-id pub-id-type="pmid">26238505</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Takagi</surname><given-names>S</given-names></name><name><surname>Chiba</surname><given-names>K</given-names></name></person-group><article-title>Ligand-dependent assembly of pregnane X receptor, constitutive androstane receptor and liver X receptor is applicable to identify ligands</article-title><source>Drug Metab Lett</source><year>2010</year><volume>4</volume><fpage>88</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.2174/187231210791292744</pub-id><?supplied-pmid 20446914?><pub-id pub-id-type="pmid">20446914</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagy</surname><given-names>L</given-names></name><name><surname>Szanto</surname><given-names>A</given-names></name><name><surname>Szatmari</surname><given-names>I</given-names></name><name><surname>Szeles</surname><given-names>L</given-names></name></person-group><article-title>Nuclear hormone receptors enable macrophages and dendritic cells to sense their lipid environment and shape their immune response</article-title><source>Physiol Rev</source><year>2012</year><volume>92</volume><fpage>739</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1152/physrev.00004.2011</pub-id><?supplied-pmid 22535896?><pub-id pub-id-type="pmid">22535896</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heneka</surname><given-names>MT</given-names></name><name><surname>Carson</surname><given-names>MJ</given-names></name><name><surname>El Khoury</surname><given-names>J</given-names></name><name><surname>Landreth</surname><given-names>GE</given-names></name><name><surname>Brosseron</surname><given-names>F</given-names></name><name><surname>Feinstein</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Neuroinflammation in Alzheimer&#x02019;s disease</article-title><source>Lancet Neurol</source><year>2015</year><volume>14</volume><fpage>388</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(15)70016-5</pub-id><?supplied-pmid 25792098?><pub-id pub-id-type="pmid">25792098</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savage</surname><given-names>JC</given-names></name><name><surname>Jay</surname><given-names>T</given-names></name><name><surname>Goduni</surname><given-names>E</given-names></name><name><surname>Quigley</surname><given-names>C</given-names></name><name><surname>Mariani</surname><given-names>MM</given-names></name><name><surname>Malm</surname><given-names>T</given-names></name><etal/></person-group><article-title>Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer&#x02019;s disease</article-title><source>J Neurosci</source><year>2015</year><volume>35</volume><fpage>6532</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4586-14.2015</pub-id><?supplied-pmid 25904803?><pub-id pub-id-type="pmid">25904803</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skerrett</surname><given-names>R</given-names></name><name><surname>Malm</surname><given-names>T</given-names></name><name><surname>Landreth</surname><given-names>G</given-names></name></person-group><article-title>Nuclear receptors in neurodegenerative diseases</article-title><source>Neurobiol Dis</source><year>2014</year><volume>72</volume><issue>Pt A</issue><fpage>104</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2014.05.019</pub-id><?supplied-pmid 24874548?><pub-id pub-id-type="pmid">24874548</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norden</surname><given-names>DM</given-names></name><name><surname>Godbout</surname><given-names>JP</given-names></name></person-group><article-title>Review: microglia of the aged brain: primed to be activated and resistant to regulation</article-title><source>Neuropathol Appl Neurobiol</source><year>2013</year><volume>39</volume><fpage>19</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2990.2012.01306.x</pub-id><?supplied-pmid 23039106?><pub-id pub-id-type="pmid">23039106</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>VH</given-names></name><name><surname>Holmes</surname><given-names>C</given-names></name></person-group><article-title>Microglial priming in neurodegenerative disease</article-title><source>Nat Rev Neurol</source><year>2014</year><volume>10</volume><fpage>217</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2014.38</pub-id><?supplied-pmid 24638131?><pub-id pub-id-type="pmid">24638131</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Streit</surname><given-names>WJ</given-names></name><name><surname>Sammons</surname><given-names>NW</given-names></name><name><surname>Kuhns</surname><given-names>AJ</given-names></name><name><surname>Sparks</surname><given-names>DL</given-names></name></person-group><article-title>Dystrophic microglia in the aging human brain</article-title><source>Glia</source><year>2004</year><volume>45</volume><fpage>208</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1002/glia.10319</pub-id><?supplied-pmid 14730714?><pub-id pub-id-type="pmid">14730714</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Morton</surname><given-names>AJ</given-names></name><name><surname>Nicholson</surname><given-names>LF</given-names></name></person-group><article-title>Microglia density decreases with age in a mouse model of Huntington&#x02019;s disease</article-title><source>Glia</source><year>2003</year><volume>43</volume><fpage>274</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1002/glia.10261</pub-id><?supplied-pmid 12898706?><pub-id pub-id-type="pmid">12898706</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasegawa-Ishii</surname><given-names>S</given-names></name><name><surname>Takei</surname><given-names>S</given-names></name><name><surname>Chiba</surname><given-names>Y</given-names></name><name><surname>Furukawa</surname><given-names>A</given-names></name><name><surname>Umegaki</surname><given-names>H</given-names></name><name><surname>Iguchi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Morphological impairments in microglia precede age-related neuronal degeneration in senescence-accelerated mice</article-title><source>Neuropathology</source><year>2011</year><volume>31</volume><fpage>20</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1789.2010.01126.x</pub-id><?supplied-pmid 20497341?><pub-id pub-id-type="pmid">20497341</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Streit</surname><given-names>WJ</given-names></name><name><surname>Xue</surname><given-names>QS</given-names></name></person-group><article-title>Microglial senescence</article-title><source>CNS Neurol Disord Drug Targets</source><year>2013</year><volume>12</volume><fpage>763</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.2174/18715273113126660176</pub-id><?supplied-pmid 24047521?><pub-id pub-id-type="pmid">24047521</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frasier</surname><given-names>M</given-names></name><name><surname>Walzer</surname><given-names>M</given-names></name><name><surname>McCarthy</surname><given-names>L</given-names></name><name><surname>Magnuson</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Haas</surname><given-names>C</given-names></name><etal/></person-group><article-title>Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein</article-title><source>Exp Neurol</source><year>2005</year><volume>192</volume><fpage>274</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2004.07.016</pub-id><?supplied-pmid 15755545?><pub-id pub-id-type="pmid">15755545</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>K</given-names></name></person-group><article-title>[Diagnosis and treatment of dementia in future--through the development of new drugs against Alzheimer disease]</article-title><source>Seishin Shinkeigaku Zasshi</source><year>2012</year><volume>114</volume><fpage>250</fpage><?supplied-pmid 22701918?><pub-id pub-id-type="pmid">22701918</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kume</surname><given-names>K</given-names></name><name><surname>Kikukawa</surname><given-names>M</given-names></name><name><surname>Hanyu</surname><given-names>H</given-names></name><name><surname>Takata</surname><given-names>Y</given-names></name><name><surname>Umahara</surname><given-names>T</given-names></name><name><surname>Sakurai</surname><given-names>H</given-names></name><etal/></person-group><article-title>Telomere length shortening in patients with dementia with Lewy bodies</article-title><source>Eur J Neurol</source><year>2012</year><volume>19</volume><fpage>905</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1111/j.1468-1331.2011.03655.x</pub-id><?supplied-pmid 22288427?><pub-id pub-id-type="pmid">22288427</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eerola</surname><given-names>J</given-names></name><name><surname>Kananen</surname><given-names>L</given-names></name><name><surname>Manninen</surname><given-names>K</given-names></name><name><surname>Hellstrom</surname><given-names>O</given-names></name><name><surname>Tienari</surname><given-names>PJ</given-names></name><name><surname>Hovatta</surname><given-names>I</given-names></name></person-group><article-title>No evidence for shorter leukocyte telomere length in Parkinson&#x02019;s disease patients</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>2010</year><volume>65</volume><fpage>1181</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1093/gerona/glq125</pub-id><?supplied-pmid 20639300?><pub-id pub-id-type="pmid">20639300</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schurks</surname><given-names>M</given-names></name><name><surname>Buring</surname><given-names>J</given-names></name><name><surname>Dushkes</surname><given-names>R</given-names></name><name><surname>Gaziano</surname><given-names>JM</given-names></name><name><surname>Zee</surname><given-names>RY</given-names></name><name><surname>Kurth</surname><given-names>T</given-names></name></person-group><article-title>Telomere length and Parkinson&#x02019;s disease in men: a nested case-control study</article-title><source>Eur J Neurol</source><year>2014</year><volume>21</volume><fpage>93</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/ene.12252</pub-id><?supplied-pmid 24010387?><pub-id pub-id-type="pmid">24010387</pub-id></element-citation></ref></ref-list></back></article>